Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 556. Отображено 100.
26-01-2012 дата публикации

USING A FIRST NETWORK TO CONTROL ACCESS TO A SECOND NETWORK

Номер: US20120022968A1
Автор: Manku Tajinder
Принадлежит:

A wireless communication device is configured to be able to communicate via both a first access point and a second access point for using the first access point to obtain validation credentials in order to permit use of the second access point to access a network. The wireless communication device comprises a processor; and a non-transitory computer readable medium having stored thereon computer executable instructions. The instructions are operable to: initiate communication with the second access point in order to access a network; obtain an access point identifier from the second access point, the access point identifier for identifying the second access point; transmit the access point identifier to a validation server via the first access point; receive validation credentials from the validation server via the first access point; and use the validation credentials to validate the wireless communication device with the second access point to obtain access to the network. 1. A wireless communication device configured to be able to communicate via both a first access point and a second access point for using the first access point to obtain validation credentials in order to permit use of the second access point to access a network , the wireless communication device comprising:a processor; and initiate communication with the second access point in order to access a network;', 'obtain an access point identifier from the second access point, the access point identifier for identifying the second access point;', 'transmit the access point identifier to a validation server via the first access point;', 'receive validation credentials from the validation server via the first access point; and', 'use the validation credentials to validate the wireless communication device with the second access point to obtain access to the network., 'a non-transitory computer readable medium having stored thereon computer executable instructions for execution by the processor, the ...

Подробнее
Номер записи: 1
09-02-2012 дата публикации

COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES

Номер: US20120035262A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMA, INC.

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. 1. A method of lowering triglycerides in a subject on statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl comprising , administering to the subject on statin therapy from 2 g to 4 g per day of a pharmaceutical composition comprising at least 96% pure ethyl-EPA thereby to lower fasting triglycerides in the subject compared to a fasting triglyceride level at a baseline prior to initial administration of the composition.2. The method of wherein the subject has serum LDL-C levels of about 40 mg/dl to about 115 mg/dl at said baseline.3. The method of wherein upon administering the composition to the subject daily for a period of 12 weeks claim 1 , the subject exhibits a reduction in fasting Lp-PLA2 compared to a fasting Lp-PLA2 level at said baseline.4. The method of wherein upon administering the composition to the subject daily for a period of 12 weeks claim 1 , the subject exhibits a reduction in fasting VLDL compared to a fasting VLDL level at said baseline.5. The method of claim 1 , wherein upon administering the composition to the subject daily for a period of 12 weeks claim 1 , the subject exhibits at least a 5% reduction in fasting triglycerides compared to said fasting triglyceride level at the baseline prior to initial administration of the composition.6. The method of claim 5 , wherein upon administering the composition to the subject daily for a period of 12 weeks claim 5 , the subject exhibits at least a 10% reduction in fasting triglycerides compared to said fasting triglyceride level at the baseline prior to initial administration of the composition.7. The method of claim 6 , wherein the administration of the composition does not result in a statistically significant increase in fasting LDL-C compared to a fasting LDL-C level at said baseline prior to ...

Подробнее
Номер записи: 2
19-04-2012 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME

Номер: US20120093922A1
Автор: Manku Mehar, Rowe Jonathan
Принадлежит: AMARIN CORPORATION PLC

The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. 1. A pharmaceutical composition comprising EPA and a cardiovascular agent , wherein the composition contains not more than 10% DHA by weight , if any.2. The composition of wherein the cardiovascular agent is an ACAT inhibitor claim 1 , an ACE inhibitor claim 1 , an alpha-blocker claim 1 , an alpha/beta-blocker claim 1 , an angiotensin II receptor antagonist claim 1 , an anti-arrythmic agent claim 1 , an antiplatelet agent claim 1 , a beta-blocker claim 1 , a calcium-channel blocker claim 1 , an HMG-CoA reductase inhibitor claim 1 , an apoA-1 mimetic claim 1 , a CETP inhibitor claim 1 , a bile acid sequestrant claim 1 , a cholesterol absorption inhibitor claim 1 , a diuretic claim 1 , a dyslipidemia agent claim 1 , an endothelin receptor antagonist claim 1 , an LDL receptor inducer claim 1 , an Lp-PLA2 inhibitor claim 1 , a squalene epoxidase inhibitor claim 1 , an LCAT activator claim 1 , a microsomal triglyceride transfer protein inhibitor claim 1 , an sPLA2 inhibitor claim 1 , a 5-lipoxygenase inhibitor claim 1 , a PPAR agonist/activator claim 1 , a thrombolytic agent claim 1 , a thyroid receptor beta activator claim 1 , a platelet aggregation inhibitor claim 1 , or an aldosterone antagonist.3. The composition of wherein the cardiovascular agent is selected from the group including of 5-LO inhibitor 6 claim 1 , A-0002 claim 1 , abciximab claim 1 , ABT-335 claim 1 , ABT-761 claim 1 , acebutolol claim 1 , acetohexamide claim 1 , adenosine claim 1 , AEGR-733 claim 1 , Aldactone claim 1 , aleglitezar claim 1 , aliskiren claim 1 , aliskiren hemifumarate claim 1 , alliin claim 1 , amiodarone claim 1 , amlodipine claim 1 , amorolfine claim 1 , amprenavir claim 1 , anacetrapib claim 1 , Angpt14 antibody claim 1 , Anti-oxLDL claim 1 , APA-01 claim 1 , apixaban ...

Подробнее
Номер записи: 3
19-04-2012 дата публикации

Methods of treating hypertriglyceridemia

Номер: US20120093924A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharma Inc

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 4
26-04-2012 дата публикации

Stable pharmaceutical composition and methods of using same

Номер: US20120100208A1
Автор: Mehar Manku
Принадлежит: Amarin Pharma Inc

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Подробнее
Номер записи: 5
03-05-2012 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20120108663A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMA, INC.

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing high-sensitivity C-reactive protein in a subject comprising , administering to a subject in need of a reduction in high-sensitivity C-reactive protein a pharmaceutical composition comprising about 4 g of at least 96% pure ethyl-EPA per day.2. The method of wherein the pharmaceutical composition contains substantially no DHA or derivative thereof.3. The method of wherein the subject has a triglyceride level of 500 mg/dl to about 2000 mg/dl.4. The method of wherein the subject has a triglyceride level of 750 mg/dl to about 2000 mg/dl.5. The method of wherein the subject is diabetic.6. The method of wherein said administration is continued for a period of at least 12 weeks.7. The method of wherein the subject exhibits at least a 10% reduction in high-sensitivity C-reactive protein after the period of at least 12 weeks compared to a baseline high-sensitivity C-reactive protein level prior to initial administration of the pharmaceutical composition.8. The method of wherein the subject exhibits at least a 20% reduction in high-sensitivity C-reactive protein after the period of at least 12 weeks compared to a baseline high-sensitivity C-reactive protein level prior to initial administration of the pharmaceutical composition.9. The method of wherein the subject exhibits at least a 35% reduction in fasting triglycerides and no statistically significant increase in LDL-C compared to a baseline triglyceride and LDL-C level prior to initial administration of the pharmaceutical composition.10. The method of wherein the subject is on concomitant statin therapy.11. A method of reducing high-sensitivity C-reactive protein in a subject having ...

Подробнее
Номер записи: 6
10-05-2012 дата публикации

USING A FIRST NETWORK TO CONTROL ACCESS TO A SECOND NETWORK

Номер: US20120116886A1
Автор: Manku Tajinder
Принадлежит: PRAVALA INC.

A wireless communication device is configured to be able to communicate via both a first access point and a second access point for using the first access point to obtain validation credentials in order to permit use of the second access point to access a network. The wireless communication device comprises a processor; and a non-transitory computer readable medium having stored thereon computer executable instructions. The instructions are operable to: initiate communication with the second access point in order to access a network; obtain an access point identifier from the second access point, the access point identifier for identifying the second access point; transmit the access point identifier to a validation server via the first access point; receive validation credentials from the validation server via the first access point; the validation credentials including at identifier of a third party, the third party sponsoring access to the second access point; use the validation credentials to validate the wireless communication device with the second access point to obtain access to the network; and present advertising information on the wireless communication device, the advertising information pertaining to the third party. 1. A wireless communication device configured to be able to communicate via both a first access point and a second access point for using the first access point to obtain validation credentials in order to permit use of the second access point to access a network , the wireless communication device comprising:a processor; and initiate communication with the second access point in order to access a network;', 'obtain an access point identifier from the second access point, the access point identifier for identifying the second access point;', 'transmit the access point identifier to a validation server via the first access point;', 'receive validation credentials from the validation server via the first access point, the validation ...

Подробнее
Номер записи: 7
17-05-2012 дата публикации

COMMUNICATION BETWEEN CLIENT AND SERVER USING MULTIPLE NETWORKS

Номер: US20120120962A1
Автор: Armstrong Nicholas, Ll Lily, Manku Tajinder, Robinson Robert, Schmidtke Jakub, Ward Paul
Принадлежит:

A system is provided to facilitate communication with a client via both a first network and a second network. The system comprises a plurality of bandwidth aggregation servers, each bandwidth aggregation server configured to aggregate data packets received from the client via both the first and second networks for transmission to a destination server; and transmit data packets to the client via both the first and second networks in accordance with a scheduling algorithm, the data packets being received from a source server. 1. A system configured to communicate with a client via both a first network and a second network , the system comprising: aggregate data packets received from the client via both the first and second networks for transmission to a destination server; and', 'transmit data packets to the client via both the first and second networks in accordance with a scheduling algorithm, the data packets being received from a source server;, 'a plurality of bandwidth aggregation servers, each bandwidth aggregation server configured to receive and store access information relating to the plurality of bandwidth aggregation server;', 'receive a request for the client to access one of the bandwidth aggregation servers;', 'determine a target bandwidth aggregation server based on a plurality of predetermined parameters; and', 'provide the client with an identify of the target bandwidth aggregation server., 'a location server configured to2. The system of claim 1 , further comprising one or more credential servers configured to receive a request for the client capable of accessing one of the first network or second network and provide the client with network credentials for accessing the other of the first network or the second network.3. The system of claim 2 , wherein the location server is further configured to identify a target one of the one or more credential servers to provide the network credentials.4. The system of claim 3 , wherein each of the credential ...

Подробнее
Номер записи: 8
17-05-2012 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME

Номер: US20120121698A1
Автор: Manku Mehar, Rowe Jonathan
Принадлежит: AMARIN PHARMA, INC.

The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. 1. A pharmaceutical composition comprising EPA and a cardiovascular agent , wherein the composition contains not more than 10% DHA by weight , if any.2. The composition of wherein the cardiovascular agent is an ACAT inhibitor claim 1 , an ACE inhibitor claim 1 , an alpha-blocker claim 1 , an alpha/beta-blocker claim 1 , an angiotensin II receptor antagonist claim 1 , an anti-arrhythmic agent claim 1 , an antiplatelet agent claim 1 , a beta-blocker claim 1 , a calcium-channel blocker claim 1 , an HMG-CoA reductase inhibitor claim 1 , an apoA-1 mimetic claim 1 , a CETP inhibitor claim 1 , a bile acid sequestrant claim 1 , a cholesterol absorption inhibitor claim 1 , a diuretic claim 1 , a dyslipidemia agent claim 1 , an endothelin receptor antagonist claim 1 , an LDL receptor inducer claim 1 , an Lp-PLA2 inhibitor claim 1 , a squalene epoxidase inhibitor claim 1 , an LCAT activator claim 1 , a microsomal triglyceride transfer protein inhibitor claim 1 , an sPLA2 inhibitor claim 1 , a 5-lipoxygenase inhibitor claim 1 , a PPAR agonist/activator claim 1 , a thrombolytic agent claim 1 , a thyroid receptor beta activator claim 1 , a platelet aggregation inhibitor claim 1 , or an aldosterone antagonist.3. The composition of wherein the cardiovascular agent is selected from the group including of 5-LO inhibitor 6 claim 1 , A-0002 claim 1 , abciximab claim 1 , ABT-335 claim 1 , ABT-761 claim 1 , acebutolol claim 1 , acetohexamide claim 1 , adenosine claim 1 , AEGR-733 claim 1 , Aldactone claim 1 , aleglitezar claim 1 , aliskiren claim 1 , aliskiren hemifumarate claim 1 , alliin claim 1 , amiodarone claim 1 , amlodipine claim 1 , amorolfine claim 1 , amprenavir claim 1 , anacetrapib claim 1 , Angpt14 antibody claim 1 , Anti-oxLDL claim 1 , APA-01 claim 1 , apixaban ...

Подробнее
Номер записи: 9
21-06-2012 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20120156285A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMA, INC.

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof 1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 2000 mg/dl comprising administering to the subject about 2 g to about 4 g per day of a pharmaceutical composition comprising at least about 96% , by weight , ethyl eicosapentaenoate for a period effective to reduce triglycerides in the subject.2. The method of wherein the composition is administered to the subject 1 to 4 times per day.3. The method of wherein the composition is present in one or more capsules.4. The method of wherein said period is about 1 to about 12 weeks.5. The method of wherein said period is about 1 to about 10 weeks.6. The method of wherein said period is about 1 to about 5 weeks.76. The method of any one of - wherein the subject has a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claims 4 , a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claims 4 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claims 4 , and a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.8. The method of wherein upon administering to the subject about 4 g of said pharmaceutical composition daily for said period claim 7 , the subject further exhibits (a) a reduction in fasting non-HDL-C compared to a fasting non-HDL-C level at a baseline prior to initial administration of the pharmaceutical composition; and (b) a reduction in fasting VLDL-C compared to a fasting VLDL-C level at a baseline prior to initial administration of the pharmaceutical composition.9. The method of wherein upon administering to the subject about 4 g of said pharmaceutical composition daily for the ...

Подробнее
Номер записи: 10
21-06-2012 дата публикации

Methods of treating hypertriglyceridemia

Номер: US20120157530A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharma Inc

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 11
21-06-2012 дата публикации

COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES

Номер: US20120157531A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMA, INC.

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. 1. A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl comprising administering to the subject about 2 g to about 4 g per day of a pharmaceutical composition comprising eicosapentaenoic acid and docosahexaenoic acid in free acid form for a period effective to reduce fasting triglycerides in the subject compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant eicosapentaenoic acid and docosahexaenoic acid for said period.2. The method of wherein the composition is administered to the subject 1 to 4 times per day.3. The method of wherein the composition is present in one or more capsules.4. The method of wherein 2 g of the composition is administered to the subject per day and each of said one or more capsules contains about 800 mg to about 1200 mg of eicosapentaenoic acid.5. The method of wherein each of said one or more capsules contains not more than about 10% by weight of any individual fatty acid selected from linolenic acid claim 4 , alpha-linolenic acid claim 4 , stearadonic acid claim 4 , eicosatrienoic acid and docasapentaenoic acid.6. The method of wherein 4 g of the composition is administered to the subject per day and each of said one or more capsules contains about 2000 mg to about 2400 mg of eicosapentaenoic acid.7. The method of wherein about 3 g of the pharmaceutical composition is administered to the subject per and wherein the composition contains about 2000 mg to about 2400 mg eicosapentaenoic acid.8. The method of wherein the period effective to reduce fasting triglycerides is about 1 week to about 15 weeks.9. The method of wherein the period effective to reduce fasting triglycerides is about 1 week to about 12weeks.10. The method of ...

Подробнее
Номер записи: 12
05-07-2012 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME

Номер: US20120172432A1
Автор: Manku Mehar, Rowe Jonathan
Принадлежит: AMARIN PHARMA, INC.

The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. 1. A method of treating a subject having baseline fasting triglycerides of at least 2000 mg/dl comprising , administering to the subject about 1 g to about 10 g per day of a pharmaceutical composition comprising at least 96% by weight ethyl eicosapentaenoate for a period effective to reduce fasting triglycerides in the subject without substantially increasing LDL-C relative to a control subject not taking said pharmaceutical composition.2. The method of wherein said period is a period effective to reduce fasting triglycerides in the subject by at least 50% without substantially increasing LDL-C relative to a control subject not taking said pharmaceutical composition.3. The method of wherein said period is a period effective to reduce fasting triglycerides in the subject by at least 55% without substantially increasing LDL-C relative to a control subject not taking said pharmaceutical composition.4. The method of wherein said period is about 1 to about 12 weeks.5. The method of wherein said period is 12 weeks.6. The method of wherein 2 g per day of the pharmaceutical composition is administered to the subject.7. The method of wherein 4 g per day of the pharmaceutical composition is administered to the subject.8. The method of wherein the composition is administered to the subject 1 to 4 times per day.9. The method of wherein the composition is present in one or more capsules. Cardiovascular disease is one of the leading causes of death in the United States and most European countries. It is estimated that over 70 million people in the United States alone suffer from a cardiovascular disease or disorder including but not limited to high blood pressure, coronary heart disease, dyslipidemia, congestive heart failure and stroke.In one embodiment, the present ...

Подробнее
Номер записи: 13
13-09-2012 дата публикации

COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES IN A SUBJECT ON CONCOMITANT STATIN THERAPY

Номер: US20120232145A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMA, INC.

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. 1. A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl comprising , administering to the subject on stable statin therapy from about 2 g to about 4 g per day of a pharmaceutical composition comprising at least 96% pure ethyl-EPA for a period effective to lower fasting triglycerides in the subject compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period.2. The method of wherein said period is about 1 to about 12 weeks.3. The method of wherein said period is about 1 to about 10 weeks.4. The method of wherein said period is about 1 to about 5 weeks.54. The method of any one of - wherein the subject has serum LDL-C levels of about 40 mg/dl to about 115 mg/dl at a baseline prior to administration of the composition.6. The method of wherein upon administering the composition to the subject daily for said period claim 5 , the subject exhibits a reduction in fasting VLDL-C compared to a fasting VLDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period.7. The method of claim 6 , wherein upon administering the composition to the subject daily for said period claim 6 , the subject exhibits at least a 20% reduction in fasting triglycerides compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period.8. The method of claim 7 , wherein upon administering the composition to the subject daily for said period claim 7 , the subject exhibits at least a 25% reduction in fasting triglycerides compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period.9. ...

Подробнее
Номер записи: 14
20-09-2012 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20120237594A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof 1. A method of reducing triglycerides in a subject in need thereof comprising: administering to the subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl about 2 g to per day of a pharmaceutical composition comprising at least about 90% , by weight , ethyl eicosapentaenoate for a period of 12 weeks to effect a reduction in triglycerides compared to a second subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl who has not received the pharmaceutical composition.2. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject 1 to 4 times per day.3. The method of wherein claim 2 , the pharmaceutical composition is present in one or more capsules.4. The method of claim 1 , wherein the subject and the second subject have one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.512. The method of claim 4 , comprising administering to the subject about 2 g of the pharmaceutical composition daily for the period of weeks to effect a reduction in fasting non-HDL-C and a reduction in fasting VLDL-C compared to the second subject.6. The method of claim 4 , comprising administering to the subject about 2 g of the pharmaceutical composition daily for the period of 12 weeks to effect a reduction in fasting triglycerides of at least about 15% compared to the second subject.7. A method of reducing triglycerides in a ...

Подробнее
Номер записи: 15
29-11-2012 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME

Номер: US20120302589A1
Автор: Manku Mehar, Rowe Jonathan
Принадлежит: AMARIN PHARMA, INC.

The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. 1. A method of treating a subject having baseline fasting triglycerides of at least 500 mg/dl comprising , administering to the subject an HMG-CoA reductase inhibitor and 4 g per day of a pharmaceutical composition comprising at least 96% by weight ethyl eicosapentaenoate for a period effective to reduce fasting triglycerides in the subject by at least 45% without substantially increasing LDL-C relative to a control subject taking a concomitant HMG-CoA reductase inhibitor without said pharmaceutical composition.2. The method of wherein said period is a period effective to reduce fasting triglycerides in the subject by at least 50% without substantially increasing LDL-C relative to a control subject taking a concomitant HMG-CoA reductase inhibitor without said pharmaceutical composition.3. The method of wherein said period is a period effective to reduce fasting triglycerides in the subject by at least 55% without substantially increasing LDL-C relative to a control subject taking a concomitant HMG-CoA reductase inhibitor without said pharmaceutical composition.4. The method of wherein said period is about 1 to about 12 weeks.5. The method of wherein said period is 12 weeks.6. The method of wherein the composition is administered to the subject 1 to 4 times per day.7. The method of wherein the composition is present in one or more capsules.8. The method of wherein the subject has a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , a baseline fasting LDL-C of about 40 mg/dl to about 115 mg/dl and a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.9. The method of ...

Подробнее
Номер записи: 16
03-01-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130004566A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof 1. A method of reducing triglycerides in a first group of subjects having a median fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl who do not receive concurrent lipid altering therapy comprising: administering orally to the subjects about 4 g per day of a pharmaceutical composition comprising at least about 96% , by weight of all fatty acids present , ethyl eicosapentaenoate and substantially no docosahexaenoic acid or its esters , for a period of at least about 12 weeks to effect a reduction in triglycerides without substantially increasing LDL-C compared to a second group of subjects having a median fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl who have not received the pharmaceutical composition and a concurrent lipid altering therapy.2. The method of claim 1 , wherein the pharmaceutical composition is administered to members of the group of subjects and the second group of subjects 1 to 4 times per day.3. The method of claim 2 , wherein the pharmaceutical composition is present in one or more capsules.4. The method of wherein the first and second groups of subjects have a median fasting baseline LDL-C from about 40 mg/dl to about 115 mg/dl.5. The method of claim 1 , wherein the first and second groups of subjects have one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.6. The method of claim 1 , comprising ...

Подробнее
Номер записи: 17
03-01-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130004567A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl who does not receive concurrent lipid altering therapy comprising: administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 96% , by weight of all fatty acids present , ethyl eicosapentaenoate and substantially no docosahexaenoic acid or its esters for a period of at least about 12 weeks to effect a reduction in triglycerides without substantially increasing LDL-C compared to placebo control.2. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject 1 to 4 times per day.3. The method of claim 2 , wherein the pharmaceutical composition is present in one or more capsules.4. The method of claim 1 , wherein the subject has a fasting baseline LDL-C from about 40 mg/dl to about 115 mg/dl.5. The method of claim 1 , wherein subject has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.6. The method of claim 1 , comprising administering to the subject about 4 g of the pharmaceutical composition daily for the period of at least about 12 weeks to effect a reduction in fasting triglycerides of at least about 10% without substantially increasing LDL-C compared to placebo control.7. The method of claim 1 , comprising administering to the subject about 4 g of ...

Подробнее
Номер записи: 18
03-01-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130004568A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl who does not receive concurrent lipid altering therapy comprising: administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 96% , by weight of all fatty acids present , ethyl eicosapentaenoate and substantially no docosahexaenoic acid or its esters for a period of about 12 weeks to effect a reduction in triglycerides without substantially increasing LDL-C compared to baseline.2. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject 1 to 4 times per day.3. The method of claim 2 , wherein the pharmaceutical composition is present in one or more capsules.4. The method of claim 1 , wherein the subject has a fasting baseline LDL-C from about 40 mg/dl to about 115 mg/dl.5. The method of claim 1 , wherein subject has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.6. The method of claim 1 , comprising administering to the subject about 4 g of the pharmaceutical composition daily for the period of at least about 12 weeks to effect a reduction in fasting triglycerides of at least about 10% without substantially increasing LDL-C compared to baseline.7. The method of claim 1 , comprising administering to the subject about 4 g of the pharmaceutical ...

Подробнее
Номер записи: 19
03-01-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130004572A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A pharmaceutical composition comprising at least 95% EPA enclosed in a capsule shell , wherein the composition has a baseline peroxide value not greater than 5 Meq/kg and upon storage of the composition at 25° C. and 60% RH for a period of 6 months , the composition has a second peroxide value not greater than 8 Meq/kg.2. The pharmaceutical composition of wherein the EPA is ethyl-EPA.3. The pharmaceutical composition of wherein the ethyl-EPA contains less than about 1% of any individual fatty acid other than ethyl eicosapentaenoate.4. The pharmaceutical composition of wherein the ethyl-EPA contains less than about 0.5% of any individual fatty acid other than ethyl eicosapentaenoate.5. The pharmaceutical composition of wherein the ethyl-EPA contains less than about 0.3% DHA claim 2 , if any.6. The pharmaceutical composition of wherein the ethyl-EPA contains substantially no DHA.7. The pharmaceutical composition of wherein the ethyl-EPA comprises about 0.1% to about 1% claim 1 , by weight claim 1 , of an antioxidant.8. The pharmaceutical composition of wherein the antioxidant is tocopherol.9. The pharmaceutical composition of wherein upon storage of the composition at 25° C. and 60% RH for a period of 6 months claim 1 , the EPA has a second peroxide value not greater than 7 Meq/kg.10. The pharmaceutical composition of wherein upon storage of the composition at ° C. and 60% RH for a period of 6 months claim 1 , the EPA has a second peroxide value not greater than 6 Meq/kg.11. The pharmaceutical composition of wherein upon storage of the composition at ° C. and 65% RH for a period of 6 months claim 1 , the EPA has a second peroxide value not greater than 12 Meq/kg.12. The pharmaceutical composition of wherein upon storage of the composition at 30° C. and 65% RH for a ...

Подробнее
Номер записи: 20
10-01-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130011471A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 130-. (canceled)31. A method of treating mixed dyslipidemia in a subject on statin therapy comprising , administering to the subject an effective amount of ethyl eicosapentaenoate daily for a period effective to reduce triglycerides and LDL-C in the subject.32. The method of comprising claim 31 , administering to the subject an effective amount of ethyl eicosapentaenoate daily to reduce fasting triglycerides by at least 10% in the subject.33. The method of comprising claim 31 , administering to the subject an effective amount of ethyl eicosapentaenoate daily to reduce fasting triglycerides by at least 15% in the subject.34. The method of comprising claim 31 , administering to the subject an effective amount of ethyl eicosapentaenoate daily to reduce fasting apolipoprotein B in the subject.35. The method of comprising claim 31 , administering to the subject an effective amount of ethyl eicosapentaenoate daily to reduce fasting VLDL-C in the subject.36. The method of comprising claim 31 , administering to the subject an effective amount of ethyl eicosapentaenoate daily to reduce fasting VLDL-C by at least 10% in the subject.37. The method of where the effective amount of ethyl eicosapentaenoate is administered to the subject in compositions each comprising about 900 mg to about 1 g of ethyl eicosapentaenoate.38. The method of where the effective amount of ethyl eicosapentaenoate is administered to the subject in compositions each comprising about 1 g of ethyl eicosapentaenoate. This application claims priority from co-pending U.S. application Ser. No. 13/458,496 filed Apr. 27, 2012, which claims priority from U.S. application Ser. No. 12/769,885 filed Apr. 29, 2010, which claims priority to U.S. provisional patent application 61/173,763, filed Apr. 29, 2009, the ...

Подробнее
Номер записи: 21
10-01-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130011472A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 130-. (canceled)31. A method of reducing triglycerides a subject with triglycerides of at least about 500 mg/dl comprising , orally administering to the subject a pharmaceutical composition comprising an amount ethyl eicosapentaenoate , present in one or more capsules comprising a capsule wall composed of gelatin and at least one plasticizer , effective to reduce triglycerides in the subject compared to a second subject with triglycerides of 500 mg/dl to 1500 mg/dl who has not received the pharmaceutical composition.32. The method of wherein the subject and the second subject have a median fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.33. The method of claim 31 , wherein the subject and the second subject have one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 31 , a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 31 , a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 31 , and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.34. The method of claim 31 , comprising administering to the subject the pharmaceutical composition daily for the period of 12 weeks to effect a reduction in triglycerides of at least about 10% without substantially increasing LDL-C in the subject compared to the second subject.35. The method of claim 31 , comprising administering to the subject the pharmaceutical composition daily for the period of 12 weeks to effect a reduction in triglycerides of at least about 25% without substantially increasing LDL-C in the subject compared to the second subject.36. The method of claim 31 , comprising administering to the subject the pharmaceutical composition daily for the period of 12 weeks to effect a reduction ...

Подробнее
Номер записи: 22
10-01-2013 дата публикации

Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy

Номер: US20130012580A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharma Inc

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Подробнее
Номер записи: 23
17-01-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130017256A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl who does not receive concurrent lipid altering therapy comprising: administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 96% , by weight of all fatty acids present , ethyl eicosapentaenoate , and substantially no docosahexaenoic acid or its esters for a period of at least 12 weeks to effect a reduction in triglycerides compared to baseline.2. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject 1 to 4 times per day.3. The method of claim 2 , wherein the pharmaceutical composition is present in one or more capsules.4. The method of claim 1 , wherein the subject has a fasting baseline LDL-C from about 40 mg/dl to about 115 mg/dl.5. The method of claim 1 , wherein subject has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/di claim 1 , a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/di claim 1 , and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.6. The method of claim 1 , comprising administering to the subject about 4 g of the pharmaceutical composition daily for the period of at least about 12 weeks to effect a reduction in fasting triglycerides of at least about 10% compared to baseline.7. The method of claim 1 , comprising administering to the subject about 4 g of the pharmaceutical composition daily for the period of at least about 12 weeks to effect a ...

Подробнее
Номер записи: 24
28-03-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130079409A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising , administering to the subject daily a pharmaceutical composition comprising an amount of eicosapentaenoic acid selected from the group consisting of about 1100 mg , about 1650 mg and about 2200 mg , and not more than about 30% , by weight of total fatty acids , docosahexaenoic acid , for a period effective to reduce triglycerides in the subject.2. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to reduce triglycerides by at least 10% in the subject.3. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to reduce triglycerides by at least 20% in the subject.4. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to reduce non-HDL-C in the subject.5. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to reduce non-HDL-C by 5% in the subject.6. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to increase HDL-C in the subject.7. The method of comprising claim 1 , administering to the subject the pharmaceutical composition daily for a period effective to increase HDL-C by 5% in the subject.8. The method of wherein the effective amount of eicosapentaenoic acid is about 1100 mg.9. The method of wherein administration of about 1100 mg of eicosapentaenoic acid per day results in an increase in plasma eicosapentaenoic acid levels of at least 200% in the subject.10. The method of wherein the effective amount of ...

Подробнее
Номер записи: 25
04-04-2013 дата публикации

DIGITAL TO ANALOG CONVERTER

Номер: US20130082853A1
Автор: Lebedev Semyon, Manku Tajinder, Muhammad Khurram
Принадлежит:

A digital-to-analog converter is disclosed. The converter includes a gradient correction module that generates a correction term based on a model of gradient error. The correction term is then applied to the signal path in the digital domain or applied to the output of the digital-to-analog converter in the analog domain. The model used to generate the correction term is based on a vertical gradient error in the array of current source elements, which may be modelled and calibrated using a second-order polynomial. Further, a digital-to-analog converter having a Nyquist DAC and an oversampled DAC is disclosed. When the oversampled DAC is enabled, the resolution of the Nyquist DAC may be increased while slowing the conversion rate. 1. A digital-to-analog converter (DAC) comprising:a data input for receiving a digital value;a current source comprising an array of current source elements, the array of current source elements for producing an analog value;a current source selector for selectively activating at least one of the current source element in the current source based on the digital value;a gradient correction module for generating a correction term based on a model of gradient error, the correction term being applied to the data input or being combined with the analog value produced by the current source; anda data output for outputting the analog value corresponding to the digital value.2. The DAC according to claim 1 , wherein the model of the gradient error is based on a vertical gradient error.3. The DAC according to claim 2 , wherein the vertical gradient error is modelled using a second-order polynomial.4. The DAC according to claim 1 , wherein the current source selector comprises a binary coded part and a thermometer coded part.5. The DAC according to claim 4 , wherein the model of the gradient error is a second-order polynomial based on a vertical gradient error claim 4 , the second-order polynomial expressed as I=c(d−d)+c(d−d) claim 4 , wherein ...

Подробнее
Номер записи: 26
11-04-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130090383A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating high triglycerides in a subject receiving statin therapy comprising , administering to the subject daily a pharmaceutical composition comprising an amount of eicosapentaenoic acid selected from the group consisting of about 1100 mg , about 1650 mg and about 2200 mg and not more than about 30% , by weight of total fatty acids , docosahexaenoic acid , for a period effective to reduce triglycerides in the subject.2. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce triglycerides by at least 10% in the subject.3. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce triglycerides by at least 15% in the subject.4. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce non-HDL-C in the subject.5. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce non-HDL-C by at least about 5% in the subject.6. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to increase HDL-C in the subject.7. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce lipoprotein associated phospholipase A2 in the subject.8. The method of comprising claim 1 , administering to the subject the pharmaceutical composition for a period effective to reduce lipoprotein associated phospholipase A2 by at least 5% in the subject.9. The method of wherein the effective amount of eicosapentaenoic acid is about 1100 mg.10. The method of wherein said administration ...

Подробнее
Номер записи: 27
18-04-2013 дата публикации

PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAME

Номер: US20130095178A1
Автор: Manku Mehar
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders. 1. A pharmaceutical composition comprising nicotinic acid in an amount of not more than about 1200 mg and eicosapentaenoic acid or a derivative thereof , wherein the composition contains not more than 10% , by weight , docosahexaenoic acid , if any.2. The composition of wherein the composition contains substantially no docosahexaenoic acid.3. The composition of wherein the eicosapentaenoic acid or derivative thereof is present in an amount of about 100 mg to about 5000 mg.4. The composition of wherein the eicosapentaenoic acid or derivative thereof is present in an amount of about 100 mg to about 1000 mg.5. The composition of wherein the eicosapentaenoic acid or derivative thereof comprises an eicosapentaenoic acid ethyl ester.6. The composition of wherein the nicotinic acid is suspended in the eicosapentaenoic acid or derivative thereof to form a suspension.7. The composition of wherein the suspension is present in a capsule.8. The composition of wherein the composition further comprises a statin.9. A pharmaceutical composition comprising nicotinic acid in an amount of not more than about 800 mg and eicosapentaenoic acid ethyl ester claim 1 , wherein the composition contains substantially no amount of docosahexaenoic acid or derivative thereof.10. A pharmaceutical composition comprising nicotinic acid in an amount of not more than about 500 mg and about 100 mg to about 1000 mg of eicosapentaenoic acid ethyl ester claim 1 , wherein the composition contains no docosahexaenoic acid claim 1 , the nicotinic acid is suspended in the eicosapentaenoic acid ethyl ester claim 1 , and the composition is present in a capsule.11. The composition of wherein the nicotinic acid is present in an amount of about 50 ...

Подробнее
Номер записи: 28
18-04-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130096197A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl comprising , administering orally to the subject 4 capsules per day , each capsule comprising about 900 mg to about 1 g of ethyl eicosapentaenoate and not more than about 3% docosahexaenoic acid or its esters , by weight of total fatty acids present , for a period of 12 weeks to effect a reduction in triglycerides in the subject.2. The method of wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 400 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 400 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a baseline fasting HDL-C of about 10 mg/dl to about 60 mg/dl.4. The method of claim 1 , wherein said administering effects a reduction in fasting triglycerides of at least about 10% without increasing LDL-C by more than 5% in the subject.5. The method of claim 1 , wherein said administering effects a reduction in apolipoprotein B in the subject.6. The method of claim 1 , wherein said administering effects a reduction in VLDL-C in the subject.7. The method of claim 1 , wherein said administration effects reduction in fasting triglycerides of at least about 20% without increasing LDL-C in the subject.8. The method of claim 1 , wherein each capsule comprises about 950 mg of ethyl eicosapentaenoate.9. The method of claim 1 , wherein each capsule comprises about 975 mg of ethyl eicosapentaenoate.10. ...

Подробнее
Номер записи: 29
25-04-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND/OR 15-HETRE AND METHODS OF USE THEREOF

Номер: US20130101533A1
Автор: Climax John, Coughlan David, Manku Mehar
Принадлежит: DIGNITY SCIENCES LIMITED

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema. 1. A composition for preventing or reducing the occurrence of erythema , the composition comprising a therapeutically effective amount of DGLA and/or 15-HETrE.2. The composition of claim 1 , wherein the composition comprises about 0.1 wt. % DGLA to about 20 wt. % DGLA.3. The composition of claim 2 , wherein the composition comprises about 10 wt. % DGLA claim 2 , about 1.0 wt % DGLA claim 2 , or about 0.1 wt. % DGLA.4. The composition of claim 1 , wherein the composition comprises about 0.01 wt. % to about 50 wt. % 15-HETrE.5. The composition of claim 4 , wherein the composition comprises about 10 wt. % 15-HETrE claim 4 , about 1.0 wt. % 15-HETrE claim 4 , about 0.1 wt. % 15-HETrE claim 4 , or about 0.01 wt. % 15-HETrE.6. The composition of claim 5 , wherein the composition comprise about 0.1 wt. % DGLA to about 20 wt. % DGLA and about 0.01 wt. % to about 50 wt. % 15-HETrE.7. A photoprotective composition for preventing or reducing the occurrence of erythema claim 5 , the composition comprising i.) a therapeutically effective amount of DGLA and/or 15-HETrE; and ii.) a sunscreen active agent.8. The composition of claim 7 , wherein the composition comprises about 0.1 wt. % DGLA to about 20 wt. % DGLA.9. The composition of claim 8 , wherein the composition comprises about 10 wt. % DGLA claim 8 , about 1.0 wt. % DGLA claim 8 , or about 0.1 wt. % DGLA.10. The composition of claim 7 , wherein the composition comprises about 0.1 wt. % to about 50 wt. % 15-HETrE.11. The composition of claim 10 , wherein the composition comprises about 10 wt. % 15-HETrE claim 10 , about 1.0 wt. % 15-HETrE claim 10 , about 0.1 wt. % 15-HETrE claim 10 , or about 0.01 wt. % 15-HETrE.12. The composition of claim 7 , ...

Подробнее
Номер записи: 30
25-04-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF USE THEREOF

Номер: US20130102575A1
Автор: Climax John, Coughlan David, Manku Mehar
Принадлежит: DIGNITY SCIENCES LIMITED

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis. 111-. (canceled)12. A method for treating or preventing acne in a subject in need thereof , the method comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of DGLA , 15-OHEPA , or 15-HETrE.13. The method of claim 12 , wherein the pharmaceutical composition comprises about 0.1 wt. % to about 20 wt. % of DGLA claim 12 , 15-OHEPA claim 12 , or 15-HETrE.14. The method of claim 13 , wherein the pharmaceutical composition comprises about 1.65 wt. % steareth-2 claim 13 , about 1.35 wt. % steareth-21 claim 13 , about 0.5 wt. % cetyl alcohol claim 13 , about 0.2 wt. % ascorbyl palmitate claim 13 , about 0.15 wt. % a-tocopherol claim 13 , about 2.0 wt. % medium-chain triglycerides (e.g. claim 13 , Crodamol GTCC) claim 13 , about 2.0 wt. % myristyl myristate claim 13 , about 4.0 wt. % isopropryl palmitate claim 13 , about 1.0 wt. % glycerin claim 13 , about 1.0 wt. % phenoxyethanol claim 13 , about 0.1 wt. % ascorbic acid claim 13 , about 0.8 wt. % carbomer claim 13 , about 0.4 wt. % xanthan gum claim 13 , about 0.5 wt. % liquid soy lecithin claim 13 , and about 0.05 wt. % Mild Care 345 fragrance.15. The method of claim 13 , wherein the pharmaceutical composition comprising 15-OHEPA further includes a therapeutically effective amount of benzoyl peroxide.16. The method of claim 15 , wherein the pharmaceutical composition comprises about 1.25% to about 10 wt. % of benzoyl peroxide.17. The method of claim 13 , wherein the pharmaceutical composition comprising 15-HETrE further includes a therapeutically effective amount of adapalene.18. The method of claim 17 , wherein the pharmaceutical composition comprises about 0. ...

Подробнее
Номер записи: 31
25-04-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130102674A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl comprising , administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 90% ethyl eicosapentaenoate , by weight of total fatty acids present , and not more than about 3% docosahexaenoic acid or its esters , by weight of total fatty acids present , for a period of 12 weeks to effect a reduction in triglycerides in the subject.2. The method of wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 400 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 400 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a baseline fasting HDL-C of about 10 mg/dl to about 60 mg/dl.4. The method of claim 1 , wherein said administering effects a reduction in fasting triglycerides of at least about 10% without increasing LDL-C by more than 5% in the subject.5. The method of claim 1 , wherein said administering effects a reduction in apolipoprotein B in the subject.6. The method of claim 1 , wherein said administering effects a reduction in VLDL-C in the subject.7. The method of claim 1 , wherein said administering effects reduction in fasting triglycerides of at least about 20% without increasing LDL-C in the subject.8. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of 500 mg/dl to about 1500 mg/dl comprising claim 1 , ...

Подробнее
Номер записи: 32
23-05-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130131170A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing large vLDL particle concentration in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl comprising administering to the subject about 2 g to about 4 g per day ethyl eicosapentaenoate thereby to produce a reduction in large vLDL particle concentration.2. The method of wherein said reduction is statistically significant.3. The method of wherein administering to the subject about 2 g to about 4 g per day of ethyl eicosapentaenoate produces a reduction in large vLDL particle concentration by comparison with a baseline large vLDL particle concentration prior to initiation of administration.4. The method of wherein the reduction in large vLDL particle concentration is at least a 2.5% reduction.5. The method of wherein the reduction in large vLDL particle concentration is at least a 10% reduction.6. The method of wherein the reduction in large vLDL particle concentration is at least a 20% reduction.7. The method of wherein the reduction in large vLDL particle concentration is at least about 24% reduction.8. The method of wherein the subject is administered about 3.8 g to about 4 g per day of ethyl eicosapentaenoate.9. The method of wherein the subject is administered ethyl eicosapentaenoate for a period of 12 weeks.10. A method of reducing small LDL particle concentration in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl comprising claim 1 , administering to the subject about 2 g to about 4 g per day of ethyl eicosapentaenoate thereby to produce a reduction in small LDL particle concentration by comparison with a baseline small LDL particle ...

Подробнее
Номер записи: 33
20-06-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130156852A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating mixed dyslipidemia in a subject on statin therapy comprising , administering to the subject 2500 mg to 5000 mg per day of ethyl eicosapentaenoate , wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 10% and a reduction in LDL-C compared to placebo control.2. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in LDL-C of at least 5% compared to placebo control.3. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 15% compared to placebo control.4. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 20% compared to placebo control.5. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 25% compared to placebo control.6. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting apolipoprotein B compared to placebo control.7. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting VLDL-C compared to placebo control.8. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting VLDL-C of at least 5% compared to placebo control.9. The method of wherein the subject exhibits a reduction in hs-CRP compared to placebo control.10. The method of wherein the subject exhibits a reduction in non-HDL-C compared to placebo control.11. The method of wherein the subject exhibits a reduction in total cholesterol compared to placebo control.12. The method of wherein the subject exhibits a reduction in non ...

Подробнее
Номер записи: 34
20-06-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130158120A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating mixed dyslipidemia in a subject on statin therapy comprising , administering to the subject a pharmaceutical composition comprising about 2500 mg to 5000 mg per day of ethyl eicosapentaenoate and not more than about 5% docosahexaenoic acid or its esters , by weight of all fatty acids , wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 10% and a reduction in LDL-C of at least 5% compared to control subjects.2. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in LDL-C of at least 5% compared to placebo control.3. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 15% compared to control subjects.4. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 20% compared to placebo control.5. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 25% compared to placebo control.6. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting apolipoprotein B compared to control subjects.7. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting VLDL-C compared to control subjects.8. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting VLDL-C of at least 5% compared to control subjects.9. The method of wherein the subject exhibits a reduction in hs-CRP compared to control subjects.10. The method of wherein the subject exhibits a reduction in non-HDL-C compared to control subjects.11. The ...

Подробнее
Номер записи: 35
27-06-2013 дата публикации

Methods of treating hypertriglyceridemia

Номер: US20130164375A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharmaceuticals Ireland Ltd

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof

Подробнее
Номер записи: 36
27-06-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130165513A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating mixed dyslipidemia in a subject on statin therapy comprising , administering to the subject a pharmaceutical composition comprising about 2500 mg to 5000 mg per day of ethyl eicosapentaenoate and not more than about 5% docosahexaenoic acid or its esters , by weight of all fatty acids , to effect a reduction in fasting triglycerides of at least 10% and a reduction in LDL-C compared to placebo control.2. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in LDL-C of at least 5% compared to placebo control.3. The method of wherein the subject exhibits a reduction in fasting triglycerides of at least 15% compared to placebo control.4. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 20% compared to placebo control.5. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 25% compared to placebo control6. The method of wherein the subject exhibits a reduction in fasting VLDL-C compared to placebo control.7. The method of wherein the subject exhibits a reduction in fasting VLDL-C of at least 5% compared to placebo control.8. The method of wherein the subject exhibits a reduction in hs-CRP compared to placebo control.9. The method of wherein the subject exhibits a reduction in non-HDL-C compared to placebo control.10. The method of wherein the subject exhibits a reduction in total cholesterol compared to placebo control.11. The method of wherein the subject exhibits a reduction in non-HDL-C claim 1 , total cholesterol and VLDL-C compared to placebo control.12. The method of wherein the subject exhibits a reduction in oxidized LDL-C compared to placebo control.13 ...

Подробнее
Номер записи: 37
04-07-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130171249A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject having fasting triglycerides of at least 500 mg/dl comprising , orally administering to the subject a pharmaceutical composition comprising about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters , by weight of all fatty acids , wherein 12 weeks of daily administration is effective to reduce fasting triglyceride levels in subjects who have fasting triglycerides levels of at least 500 mg/dl.2. The method of claim 1 , wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.4. The method of claim 1 , wherein 12 weeks of said daily administration is effective to reduce triglycerides by at least about 30% without increasing LDL-C in subjects who have fasting triglycerides levels of at least 500 mg/dl.5. The method of claim 1 , wherein 12 weeks of said daily administration is effective to reduce apolipoprotein B in subjects who have fasting triglycerides levels of at least 500 mg/dl.6. The method of claim 1 , wherein 12 weeks of said daily administration is effective to reduce VLDL-C in subjects who have fasting triglycerides levels of at least 500 mg/dl.7. The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of 500 mg/dl to 1500 mg/dl.8. ...

Подробнее
Номер записи: 38
04-07-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130171250A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides comprising , identifying a group of subjects having a median triglyceride level of at least 500 mg/dl and orally administering daily to at least one subject in the group of subjects a pharmaceutical composition comprising about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters , by weight of all fatty acids , for a period of 12 weeks to reduce fasting triglycerides in the at least one subject.2. The method of claim 1 , wherein the group of subjects has a median fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the group of subjects has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.4. The method of claim 1 , wherein 12 weeks of said administering is effective to reduce triglycerides by at least about 30% without increasing LDL-C in the at least one subject.512. The method of claim 1 , wherein weeks of said administering is effective to reduce apolipoprotein B in the at least one subject.612. The method of claim 1 , wherein weeks of said administering is effective to reduce VLDL-C in the at least one subject.7. The method of claim 1 , wherein the group of subjects has a median fasting baseline triglyceride level of 500 mg/dl to 1500 mg/dl.8. The method of claim 1 , wherein the composition is present in one or more dosage units.9. The ...

Подробнее
Номер записи: 39
04-07-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130171251A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of reducing triglycerides comprising , identifying a group of subjects having a median triglyceride level of at least 500 mg/dl and orally administering daily to at least one subject in the group of subjects about 2500 mg to about 5000 mg of ethyl eicosapentaenoate , present in one or more capsules , wherein upon 12 weeks of said administering the at least one subject exhibits a reduction in triglycerides without an increase of LDL-C of more than 5%.2. The method of claim 1 , wherein the group of subjects has a median fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the group of subjects has one or more of: a median baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a median baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a median baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.4. The method of claim 1 , wherein 12 weeks of said administering is effective to reduce triglycerides by at least about 30% without increasing LDL-C in the at least one subject.5. The method of claim 1 , wherein 12 weeks of said administering is effective to reduce apolipoprotein B in the at least one subject.6. The method of claim 1 , wherein 12 weeks of said administering is effective to reduce VLDL-C in the at least one subject.7. The method of claim 1 , wherein the group of subjects have a median fasting baseline triglyceride level of 500 mg/dl to 1500 mg/dl.8. The method of claim 1 , wherein the ethyl eicosapentaenoate is present in one or more dosage units.9. The method of claim 8 , wherein the dosage units are capsules.10. A method of reducing triglycerides comprising claim ...

Подробнее
Номер записи: 40
04-07-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130172413A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating a subject with fasting triglycerides of at least 500 mg/dl comprising , orally administering to the subject daily for a period of 12 weeks about 2500 mg to 5000 mg of ethyl eicosapentaenoate to lower triglycerides in the subject by at least 25% without increasing LDL-C by more than 5%.2. The method of wherein the subject has a fasting baseline LDL-C from about 50 mg/dl to about 300 mg/dl.3. The method of claim 1 , wherein the subject has one or more of: a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , and/or a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.4. The method of claim 1 , comprising administering to the subject the pharmaceutical composition daily for the period of 12 weeks to effect a reduction in triglycerides of at least about 30% without increasing LDL-C in the subject.5. The method of claim 1 , comprising administering to the subject the pharmaceutical composition daily for the period of 12 weeks to effect a reduction in apolipoprotein B in the subject.6. The method of claim 1 , comprising administering to the subject the pharmaceutical composition daily for the period of 12 weeks to effect a reduction in VLDL-C in the subject.7. The method of claim 1 , wherein the composition is present in one or more dosage units.8. The method of claim 7 , wherein the dosage units are capsules. This application claims priority from co-pending U.S. Application Ser. No. 13/685,291 filed on Nov. 26, 2012, which claims priority to U.S. application Ser. No. 13/614,111 filed Sep. 13, 2012, which claims priority to U.S. application Ser. No. 13/458,496 filed ...

Подробнее
Номер записи: 41
25-07-2013 дата публикации

COMPOSITIONS AND METHODS FOR LOWERING LEVELS OF HIGH-SENSITIVITY (HS-CRP) IN A SUBJECT

Номер: US20130189355A1
Автор: Braeckman Renee, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In some embodiments, the method comprises lowering high sensitivity CRP (hs-CRP) levels in a subject including, for example, a subject with a HbAvalue of about 5.00%-8.50% or at least about 6.8%. 1. A method of lowering a high-sensitivity CRP (hs-CRP) level in a subject having a HbAlevel of at least about 6% , the method comprising administering to the subject daily a pharmaceutical composition comprising about 3.5 g to about 4 g of eicosapentaenoic acid or a derivative thereof for a period of time effective to lower the hs-CRP level in the subject.2. The method of claim 1 , wherein the subject has a baseline triglyceride level of about 150-499 mg/dl.3. The method of claim 2 , wherein the subject is on statin therapy or stable statin therapy.4. The method of claim 1 , wherein the pharmaceutical composition comprises at least 90% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.5. The method of claim 1 , wherein the pharmaceutical composition is encapsulated in a capsule.6. The method of claim 5 , wherein the capsule comprises gelatin.7. The method of claim 6 , wherein 1 to 4 of said capsules are administered to the subject each day.8. The method of claim 1 , wherein the subject has a HbAlevel of at least about 6.8%.9. The method of claim 8 , wherein the period of time is about 12 weeks and the hs-CRP level is lowered in the subject by at least about 5% compared to a placebo controlled subject who is on stable statin therapy and has not received the pharmaceutical composition.10. The method of claim 9 , wherein the hs-CRP level is reduced by at least about 10% claim 9 , compared to the placebo controlled subject.11. A method of lowering high- ...

Подробнее
Номер записи: 42
01-08-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME

Номер: US20130195972A1
Автор: Manku Mehar, Rowe Jonathan
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. 1. A method of treating a subject having baseline fasting triglycerides of at least 500 mg/dl comprising , administering to the subject an HMG-CoA reductase inhibitor and 4 g per day of a pharmaceutical composition comprising at least 96% by weight ethyl eicosapentaenoate for a period effective to reduce fasting triglycerides by at least 45% without substantially increasing LDL-C relative to a control subject taking a concomitant HMG-CoA reductase inhibitor without said pharmaceutical composition.2. The method of wherein said period is a period effective to reduce fasting triglycerides by at least 50% without substantially increasing LDL-C relative to a control subject taking a concomitant HMG-CoA reductase inhibitor without said pharmaceutical composition.3. The method of wherein said period is a period effective to reduce fasting triglycerides by at least 55% without substantially increasing LDL-C relative to a control subject taking a concomitant HMG-CoA reductase inhibitor without said pharmaceutical composition.4. The method of wherein said period is about 1 to about 12 weeks.5. The method of wherein said period is 12 weeks.6. The method of wherein the composition is administered to the subject 1 to 4 times per day.7. The method of wherein the composition is present in one or more capsules.8. The method of wherein the subject has a baseline fasting non-HDL-C of about 200 mg/dl to about 300 mg/dl claim 1 , a baseline fasting total cholesterol of about 250 mg/dl to about 300 mg/dl claim 1 , a baseline fasting VLDL-C of about 140 mg/dl to about 200 mg/dl claim 1 , a baseline fasting LDL-C of about 40 mg/dl to about 115 mg/dl and a baseline fasting HDL-C of about 10 mg/dl to about 80 mg/dl.9. The method of wherein upon administering to the subject about ...

Подробнее
Номер записи: 43
26-09-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130252989A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating mixed dyslipidemia in a subject in need thereof comprising , administering to the subject daily a statin and 2500 mg to about 5000 mg of ethyl eicosapentaenoate to reduce fasting triglycerides and LDL-C relative to subjects having mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.2. The method of wherein said administering step reduces fasting triglycerides by at least 10% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.3. The method of wherein said administering step reduces fasting triglycerides by at least 15% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.4. The method of wherein said administering step reduces fasting triglycerides by at least 20% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.5. The method of wherein said administering step reduces fasting triglycerides by at least 25% and LDL-C by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.6. The method of wherein said administering step reduces fasting apolipoprotein B relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.7. The method of wherein said administering step reduces fasting apolipoprotein B by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.8. The method of wherein said administering step reduces fasting VLDL-C relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.9. The method of wherein said administering ...

Подробнее
Номер записи: 44
26-09-2013 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20130252990A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating hypertiglyceridemia in a subject in need thereof comprising , administering to the subject daily a statin and 2500 mg to about 5000 mg of ethyl eicosapentaenoate to reduce fasting triglycerides and LDL-C relative to subjects having hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.2. The method of wherein said administering step reduces fasting triglycerides by at least 10% relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.3. The method of wherein said administering step reduces fasting triglycerides by at least 15% relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.4. The method of wherein said administering step reduces fasting triglycerides by at least 20% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.5. The method of wherein said administering step reduces fasting triglycerides by at least 25% and LDL-C by at least 5% relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.6. The method of wherein said administering step reduces fasting apolipoprotein B relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.7. The method of wherein said administering step reduces fasting apolipoprotein B by at least 5% relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.8. The method of wherein said administering step reduces fasting VLDL-C relative to subjects with hypertiglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.9. The method of wherein said ...

Подробнее
Номер записи: 45
26-09-2013 дата публикации

METHODS OF TREATING MIXED DYSLIPIDEMIA

Номер: US20130253030A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A method of treating mixed dyslipidemia in a subject comprising , administering to the subject daily a statin and about 4 g of ethyl eicosapentaenoate to effect a reduction in fasting triglycerides and LDL-C relative to subjects having mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.2. The method of wherein said administering step reduces fasting triglycerides by at least 10% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.3. The method of wherein said administering step reduces fasting triglycerides by at least 15% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.4. The method of wherein said administering step reduces fasting triglycerides by at least 20% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.5. The method of wherein said administering step reduces fasting triglycerides by at least 25% and LDL-C by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.6. The method of wherein said administering step reduces fasting apolipoprotein B relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.7. The method of wherein said administering step reduces fasting apolipoprotein B by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.8. The method of wherein said administering step reduces fasting VLDL-C relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.9. The method of wherein said administering step reduces fasting VLDL-C by at least 15% relative to subjects with mixed dyslipidemia who are ...

Подробнее
Номер записи: 46
26-09-2013 дата публикации

METHODS OF TREATING MIXED DYSLIPIDEMIA

Номер: US20130253031A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A method of treating hypertriglyceridemia in a subject comprising , administering to the subject daily a statin and about 4 g of ethyl eicosapentaenoate to effect a reduction in fasting triglycerides and LDL-C relative to subjects having hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate.2. The method of wherein said administering step reduces fasting triglycerides by at least 10% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.3. The method of wherein said administering step reduces fasting triglycerides by at least 15% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.4. The method of wherein said administering step reduces fasting triglycerides by at least 20% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.5. The method of wherein said administering step reduces fasting triglycerides by at least 25% and LDL-C by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.6. The method of wherein said administering step reduces fasting apolipoprotein B relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.7. The method of wherein said administering step reduces fasting apolipoprotein B by at least 5% relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.8. The method of wherein said administering step reduces fasting VLDL-C relative to subjects with mixed dyslipidemia who are receiving a statin without said ethyl eicosapentaenoate.9. The method of wherein said administering step reduces fasting VLDL-C by at least 15% relative to subjects with mixed dyslipidemia who ...

Подробнее
Номер записи: 47
10-10-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF REDUCING SEBUM PRODUCTION USING SAME

Номер: US20130267598A1
Автор: Climax John, Coughlan David, Downes Bill, Manku Mehar
Принадлежит:

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production. 1. A method for reducing sebum production in a subject in need thereof , the method comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of DGLA , 15-OHEPA , or 15-HETrE.2. The method of claim 1 , wherein the pharmaceutical composition comprises about 0.1% to about 20 wt. % of DGLA claim 1 , 15-HETrE and/or 15-OHEPA.3. The method of claim 2 , wherein the pharmaceutical composition comprises about 1.65 wt. % steareth-2 claim 2 , about 1.35 wt. % steareth-21 claim 2 , about 0.5 wt. % cetyl alcohol claim 2 , about 0.2 wt. % ascorbyl palmitate claim 2 , about 0.15 wt. % a-tocopherol claim 2 , about 2.0 wt. % medium-chain triglycerides (e.g. claim 2 , Crodamol GTCC) claim 2 , about 2.0 wt. % myristyl myristate claim 2 , about 4.0 wt. % isopropyl palmitate claim 2 , about 1.0 wt. % glycerin claim 2 , about 1.0 wt. % phenoxyethanol claim 2 , about 0.1 wt. % ascorbic acid claim 2 , about 0.8 wt. % carbomer claim 2 , about 0.4 wt. % xanthan gum claim 2 , about 0.5 wt. % liquid soy lecithin claim 2 , and about 0.05 wt. % Mild Care 345 fragrance.4. The method of claim 2 , wherein the pharmaceutical composition comprising DGLA claim 2 , 15-OHEPA claim 2 , or 15-HETrE further includes a therapeutically effective amount of a retinoid analogue.5. The method of claim 4 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 1 wt. % of the retinoid analogue.6. The method of claim 1 , wherein the step of administering comprises topically applying the composition to an area of the skin.7. The method of claim 6 , wherein applying the composition results in about a 10% claim 6 , 20% claim 6 , 30% claim 6 , 40% claim 6 , 50% 60% claim 6 , 70% ...

Подробнее
Номер записи: 48
17-10-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF REDUCING SEBUM PRODUCTION USING SAME

Номер: US20130274338A1
Автор: Climax John, Coughlan David, Downes Bill, Manku Mehar
Принадлежит:

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production. 1. A pharmaceutical composition comprising 15-HETrE and a retinoid analogue.2. The pharmaceutical composition of wherein the retinoid analogue is adapalene.3. A topically deliverable pharmaceutical composition comprising a therapeutically effective amount of 15-HETrE and a retinoid analogue.4. The topically deliverable composition of wherein the retinoid analogue is adapalene.5. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene.6. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises about 0.01 wt. % to about 20 wt. % of 15-HETrE.7. The pharmaceutical composition of claim 1 , wherein the composition is a cream.8. A method of treating or inhibiting development of acne in a subject in need thereof claim 1 , the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of .9. The method of claim 8 , wherein the step of administering comprises applying the pharmaceutical composition to an area of skin of the subject afflicted with acne lesions.10Propionibacterium acnes.. The method of claim 8 , wherein the acne is associated with11. The method of claim 8 , wherein the pharmaceutical composition is administered to the subject once a day claim 8 , twice a day claim 8 , or three times a day.12. The method of claim 8 , wherein the pharmaceutical composition is a cream.13. The method of claim 8 , wherein the pharmaceutical composition comprises about 0.1 wt. % to about 20 wt. % of 15-HETrE.14. The method of claim 8 , wherein the pharmaceutical composition comprises about 0.05 wt. % to about 0.3 wt. % of adapalene. This ...

Подробнее
Номер записи: 49
24-10-2013 дата публикации

COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY

Номер: US20130281534A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. 114-. (canceled)15. A method of lowering triglycerides in a subject having mixed dyslipidemia on stable statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl , the method comprising orally administering to the subject daily a pharmaceutical composition comprising about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its esters , by weight of all fatty acids , for a period of at least about 4 weeks.16. The method of claim 15 , wherein the subject has coronary heart disease or a coronary heart disease risk equivalent.17. The method of claim 16 , wherein the subject has an LDL-C level of 40 mg/dl to 100 mg/dl prior to the administering step.18. The method of claim 15 , wherein LDL-C is reduced in the subject upon 4 weeks of said administering.19. The method of claim 18 , wherein the subject exhibits a reduction in one or more of: non-HDL-C claim 18 , VLDL-C claim 18 , Lp-PLA2 claim 18 , apolipoprotein B claim 18 , total cholesterol claim 18 , HDL-C or VLDL-TG.20. The method of claim 15 , wherein the subject exhibits a reduction in one or more of: non-HDL-C claim 15 , VLDL-C claim 15 , Lp-PLA2 claim 15 , apolipoprotein B claim 15 , total cholesterol claim 15 , HDL-C or VLDL-TG.21. The method of claim 15 , wherein the composition is present in one or more dosage units claim 15 ,22. A method of lowering triglycerides in a subject on stable statin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl and an LDL-C level of 40 mg/dl to 100 mg/dl claim 15 , the method comprising orally administering to the subject daily a pharmaceutical composition claim 15 , present more than one dosage unit claim 15 , comprising about 4 g of ethyl eicosapentaenoate and not more than about 4% docosahexaenoic acid or its ...

Подробнее
Номер записи: 50
14-11-2013 дата публикации

METHOD AND APPARATUS FOR GENERATING DEDICATED DATA CHANNELS IN BACKSCATTER RFID SYSTEMS

Номер: US20130299579A1
Автор: Manku Tajinder
Принадлежит:

An antenna apparatus for backscattering an incoming radio frequency (RF) signal includes an antenna for backscattering the incoming RF signal in accordance with a reflection coefficient characteristic of the antenna. A variable impedance circuit includes an output electrically connected to the antenna. A low pass delta sigma modulator is coupled to the variable impedance circuit and digitally controls the output of the variable impedance circuit, such that the reflection coefficient of the antenna is adjusted based on the output of the variable impedance circuit. 1. An antenna apparatus for backscattering an incoming radio frequency (RF) signal comprising:an antenna for backscattering the incoming RF signal in accordance with a reflection coefficient characteristic of the antenna;a variable impedance circuit having an output electrically connected to the antenna; andat least one low pass delta sigma (ΔΣ) modulator coupled to the variable impedance circuit and digitally controlling the output of the variable impedance circuit;wherein the reflection coefficient (Γ) of the antenna is adjusted based on the output of the variable impedance circuit.2. The antenna apparatus of wherein an output of the at least one low pass delta sigma modulator switches the output of the variable impedance circuit between two states to adjust the reflection coefficient.3. The antenna apparatus of wherein an input signal applied to the low pass delta sigma modulator consists of one of a complex modulation signal offset from the incoming radio frequency signal by +/−ω.4. The antenna apparatus of wherein the complex modulation signal consists of one of a GMSK claim 3 , QPSK claim 3 , nPSK claim 3 , nQAM claim 3 , and an OFDM signal.5. The antenna apparatus of wherein an output of the low pass delta sigma modulator is one of a return to zero (RTZ) and a non-return to zero (NRZ) type signal.6. The antenna apparatus of further comprising at least a second low pass delta sigma modulator coupled ...

Подробнее
Номер записи: 51
14-11-2013 дата публикации

METHOD AND APPARATUS FOR GENERATING DEDICATED DATA CHANNELS IN BACKSCATTER RFID SYSTEMS USING BAND-PASS MODULATION

Номер: US20130300619A1
Автор: Manku Tajinder
Принадлежит:

An antenna apparatus for backscattering an incoming radio frequency (RF) signal includes an antenna for backscattering the incoming RF signal in accordance with a reflection coefficient characteristic of the antenna. A variable impedance circuit includes an output electrically connected to the antenna. A band-pass delta sigma modulator is coupled to the variable impedance circuit and digitally controls the output of the variable impedance circuit, such that the reflection coefficient of the antenna is adjusted based on the digitally controlled output of the variable impedance circuit. In an RFID network, the apparatus and method reduces the effect of DC offset in the reader device and the effects of the reader device's phase noise, while allowing for complex modulations. 1. An antenna apparatus for backscattering an incoming radio frequency (RF) signal comprising:an antenna for backscattering the incoming RF signal in accordance with a reflection coefficient characteristic of the antenna;a variable impedance circuit having an output electrically connected to the antenna; anda band-pass delta sigma (ΔΣ) modulator coupled to the variable impedance circuit and digitally controlling the output of the variable impedance circuit;wherein the reflection coefficient (Γ) of the antenna is adjusted based on the digitally controlled output of the variable impedance circuit.2. The antenna apparatus of claim 1 , the antenna apparatus comprising part of a tag terminal electromagnetically coupled to a reader device within a radio frequency identification (RFID) system wherein clocking of the band-pass delta sigma modulator is generated via a clock circuit within the tag terminal.3. The antenna apparatus of claim 1 , the antenna apparatus comprising part of a tag terminal electromagnetically coupled to a reader device within a radio frequency identification (RFID) system wherein clocking of the band-pass delta sigma modulator is generated based on a carrier signal frequency of the ...

Подробнее
Номер записи: 52
05-12-2013 дата публикации

Method and Apparatus for Generating Dedicated Data Channels in Inductive Coupled RFID Systems

Номер: US20130324032A1
Автор: Tajinder Manku
Принадлежит: Individual

An inductive coupling apparatus for modifying an incoming radio frequency (RF) signal includes an inductive element for modifying the incoming RF signal in accordance with a coupled impedance characteristic of the inductive element. A variable impedance circuit includes an output electrically coupled to the inductive element. A low pass delta sigma modulator is coupled to the variable impedance circuit and digitally controls the output of the variable impedance circuit, the coupled impedance of the inductive element being adjusted based on the output of the variable impedance circuit.

Подробнее
Номер записи: 53
05-12-2013 дата публикации

Method and Apparatus for Generating Dedicated Data Channels in Inductive Coupled RFID Systems Using Band-Pass Modulation

Номер: US20130324033A1
Автор: Tajinder Manku
Принадлежит: Individual

An inductive coupling apparatus for modifying an incoming radio frequency (RF) signal includes an inductive element. A variable impedance circuit includes an output electrically coupled to the inductive element. A band-pass delta sigma modulator is coupled to the variable impedance circuit and digitally controls the output of the variable impedance circuit. The incoming RF signal is modified as the coupled impedance of the inductive element is adjusted in accordance with the output of the variable impedance circuit.

Подробнее
Номер записи: 54
05-12-2013 дата публикации

Process for preparation of levonorgestrel

Номер: US20130324748A1
Автор: Girij Pal Singh, Himanshu Madhav Godbole, Kishor Gulabrao Mehare, Swapnil Ajit ZADBUKE
Принадлежит: Lupin Ltd

The present invention provides an improved process for preparation of levonorgestrel (3) which comprises of hydrolysis of 13β-ethyl-3-methoxy-17α-ethynyl-gona-2,5(10)-dien-17β-ol (2) with an acid in aprotic solvent. The present invention also provides a novel process for purification of crude levonorgestrel (3) by recrystallization from N,N-dimethyl formamide-water; methanol-water mixture.

Подробнее
Номер записи: 55
12-12-2013 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20130331447A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of lowering high-sensitivity C-reactive protein in a subject in need thereof comprising , administering to the subject daily (a) about 4 g of a pharmaceutical composition comprising at least 96% pure ethyl-EPA and (b) a statin.2. The method of wherein the pharmaceutical composition contains substantially no DHA or derivative thereof.3. The method of wherein the subject has a triglyceride level of 500 mg/dl to about 2000 mg/dl.4. The method of wherein the subject has a triglyceride level of 750 mg/dl to about 2000 mg/dl.5. The method of wherein the subject is diabetic.6. The method of wherein said administration is continued for a period of at least 12 weeks.7. The method of wherein the subject exhibits at least a 20% reduction in high-sensitivity C-reactive protein after the period of at least 12 weeks compared to baseline.8. The method of wherein the subject exhibits at least a 35% reduction in fasting triglycerides compared to baseline and no statistically significant increase in LDL9. A pharmaceutical composition comprising an effective amount of at least 96% pure E-EPA and an HMG-CoA inhibitor for use in reducing hsCRP in patients with TGs above 500 mg/dl. This application is a continuation of U.S. application Ser. No. 13/198,221, filed Aug. 4, 2011, which is a continuation of U.S. application Ser. No. 12/702,889, filed Feb. 9, 2010, which claims priority to U.S. provisional application Ser. No. 61/151,291 filed Feb. 10, 2009, and U.S. provisional application Ser. No. 61/173,755 filed Apr. 29, 2009, each of which are incorporated by reference herein in their entireties.Cardiovascular disease is one of the leading causes of death in the ...

Подробнее
Номер записи: 56
12-12-2013 дата публикации

COMPOSITIONS COMPRISING 20-CARBON FATTY ACIDS AND METHODS OF MAKING AND USING SAME

Номер: US20130331448A1
Автор: Climax John, Manku Mehar, Rowe Jonathan
Принадлежит: DIGNITY SCIENCES LIMITED

The present disclosure provides a process for producing 20-carbon fatty acids from a plant seed oil, the process comprising: a) providing a plant seed oil comprising fatty acids, wherein the fatty acids include 18-carbon fatty acids; and b) elongating the fatty acids by two carbon atoms to produce a composition comprising 20-carbon fatty acids. 1. A process for producing 20-carbon fatty acids from a plant seed oil comprising 18-carbon fatty acids , the process comprising elongating at least a portion of the 18-carbon fatty acids present in the plant seed oil by two carbon atoms to produce 20-carbon fatty acids.2. The process of wherein said elongating step comprises contacting the 18-carbon fatty acids with an enzyme.3. The process of wherein the enzyme comprises elongase.4. The process of further comprising a step of esterifying at least a portion of the 20-carbon fatty acids.5. The process of claim 1 , wherein the 18-carbon fatty acids include a plurality of different 18-carbon fatty acids.6. The process of claim 5 , wherein the 18-carbon fatty acids comprise one or more of SDA claim 5 , GLA claim 5 , and ALA claim 5 , and the 20-carbon fatty acids comprise one or more of ETA claim 5 , ETE and DGLA.7. The process of further comprising a step of extracting the 18-carbon fatty acids from the plant seed oil prior to the elongating step.8. The process of wherein the 18-carbon fatty acids are extracted from the plant seed oil by organic solvent extraction or supercritical fluid extraction.9. The process of wherein the supercritical fluid extraction comprises COsupercritical fluid extraction (CO-SFE).10. The process of further comprising purifying the 20-carbon fatty acids claim 9 , optionally by urea fractionization claim 9 , low-temperature crystallization claim 9 , chromatographic separation claim 9 , HPLC claim 9 , or distillation.11. The process of claim 10 , wherein the 20-carbon fatty acids are purified to produce 20-carbon fatty acids having a purity selected ...

Подробнее
Номер записи: 57
16-01-2014 дата публикации

Neonatal Laryngeal Mask Airway-NLMA (NLMA-0 and NLMA-1)

Номер: US20140014113A1
Автор: Ali Ayoob, Ali Samreen Mehar
Принадлежит:

The disclosed Neonatal Laryngeal Mask Airway-0 and 1 (NLMA-0, NLMA-1) device includes an inflatable cuff, an airway tube, a connector, backplate with an aperture. The cuff is insertable through mouth of the patient to an inserted location within patient oropharynx. The cuff of the NLMA surrounds glottis opening and opening in the backplate of the NLMA. The airway tube is a communicating passage between connector and inflatable cuff. The connector is attached to the outer end of the airway tube and inflatable cuff attached to the inner portion of the airway tube. 1. A Neonatal laryngeal mask airway size 0 (NLMA-0): The device as claimed is an artificial airway device to facilitate lung ventilation in premature infant with gestational age of 30 weeks of gestation to 35 weeks of gestation or birth weight 1500 grams to 2500 grams , as well as when the mask is positioned for sealing the airway tube to the laryngeal inlet , this device can be used to establish reliable airway in an emergent situation without the need of endotracheal intubation.2. The device as claimed in is designed to administer surfactant to premature infant at gestational age of 30 weeks to 35 weeks of gestation claim 1 , gestation or 1500 grams to 2500 grams weight infant suffering from respiratory distress syndrome. This device is capable of introducing a tracheal suction catheter device through connector claim 1 , via tracheal tube to the inflatable cuff into the tracheal opening and airway of a patient claim 1 , to deliver surfactant into the tracheal without endotracheal intubation in these premature infants.3. A Neonatal laryngeal mask airway size 1 (NLMA-1): The device as claimed is an artificial airway device to facilitate lung ventilation in premature infant with gestational age of 35 weeks of gestation to 3 months of life or birth weight of 2500 grams to 5000 grams claim 1 , as well as when the mask is positioned for sealing the airway tube to the laryngeal inlet claim 1 , this device can be ...

Подробнее
Номер записи: 58
16-01-2014 дата публикации

TRANSMISSION APPARATUS FOR A WIRELESS DEVICE

Номер: US20140016719A1
Автор: Manku Tajinder
Принадлежит:

A transmission apparatus for a wireless device, comprising: an antenna for receiving an original signal and for backscattering a modulated signal containing information from the wireless device; a variable impedance coupled to the antenna, the variable impedance having an impedance value; and, a decoder coupled to the variable impedance for modulating the impedance value, and thereby a backscattering coefficient for the antenna, in accordance with the information to generate the modulated signal. 1. A transmission apparatus for a wireless device , comprising:an antenna for receiving an original signal and for backscattering a modulated signal containing information from the wireless device;a variable impedance coupled to the antenna, the variable impedance having an impedance value; and,a decoder coupled to the variable impedance for modulating the impedance value, and thereby a backscattering coefficient for the antenna, in accordance with the information to generate the modulated signal.2. The transmission apparatus of wherein the variable impedance is coupled in series with the antenna.3. The transmission apparatus of wherein the wireless device is powered by energy from the original signal.4. The transmission apparatus of wherein the variable impedance includes an array of impedances and respective switches.5. The transmission apparatus of wherein the decoder includes a backscattering coefficient to impedance value decoder.6. The transmission apparatus of wherein the information is an N-bit digital waveform.7. The transmission apparatus of wherein the N-bit digital waveform is applied to the decoder to produce a control signal for the variable impedance that is related to the N-bit digital waveform.8. The transmission apparatus of wherein a change in the impedance value backscatters the original signal to produce the modulated signal claim 7 , the modulated signal being a frequency offset form of the N-bit digital waveform.9. The transmission apparatus of ...

Подробнее
Номер записи: 59
16-01-2014 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20140017306A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A pharmaceutical composition , comprising: fatty acids including (a) eicosapantaenoic acid in an amount selected from 1000 mg , 1650 mg and 2200 mg; (b) docosahexaenoic acid in an amount of about 20% , by weight of total fatty acids; and docosapentaenoic acid in an amount of about 5% , by weight of total fatty acids.2. The pharmaceutical composition of wherein the eicosapantaenoic acid is present in an amount of about 1000 mg.3. The pharmaceutical composition of wherein the eicosapantaenoic acid is present in an amount of about 1650 mg.4. The pharmaceutical composition of wherein the eicosapantaenoic acid is present in an amount of about 2200 mg.5. The composition of wherein the composition is present in one or more dosage units.6. The composition of wherein the dosage units comprise capsules.7. A method of reducing triglycerides in a subject in need thereof comprising claim 6 , administering to the subject daily a composition of .8. The method of wherein the subject has very high serum triglycerides and is at risk of pancreatitis. This application claims priority from co-pending U.S. application Ser. No. 13/685,281 filed Nov. 26, 2012, which claims priority to U.S. patent Ser. No. 13/614,146 filed Sep. 13, 2012, now U.S. Pat. No. 8,501,225, which claims priority to U.S. application Ser. No. 13/458,496 filed Apr. 27, 2012, now U.S. Pat. No. 8,445,003, which claims priority from U.S. application Ser. No. 12/769,885 filed Apr. 29, 2010, now U.S. Pat. No. 8,298,554 which claims priority to U.S. provisional patent application 61/173,763, filed Apr. 29, 2009, the entireties of each of which are hereby Incorporated by reference herein.Mixed omega-3 fatty acid esters are typically encapsulated in type 2a gelatin capsules containing gelatin (˜43.4%), glycerol (˜20%) and ...

Подробнее
Номер записи: 60
30-01-2014 дата публикации

TRANSCEIVER FILTER AND TUNING

Номер: US20140029480A1
Автор: Manku Tajinder, MOTI Zohaib
Принадлежит: BlackBerry Limited

A radio transceiver including a transmitter and a receiver. A filter coupled to an output of the transmitter, the filter has one or more inductors and one or more capacitors, where the filter is tuned by varying one or more capacitance values of the one or more capacitors in the filter to tune the filter. The one or more capacitors are Barium Strontium Titanate (BST) ceramic integrated capacitors that are each tuned by application of a bias voltage thereto. A filter tuner circuit is configured to apply the bias voltage to the one or more capacitors, where the bias voltage is initially established as a stored initial value, and where the bias voltage is refined by a proportional-integral-derivative (PID) controller configured to optimize a power within the transceiver. This abstract is not to be considered limiting since various implementations may incorporate more, fewer or different elements. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. A radio transceiver comprising: a multi-band transmitter and a multi-band receiver , where the transmitter and receiver are configured to operate in full duplex with a transmitter channel for use by the transmitter and a receiver channel for use by the receiver;an antenna shared by the transmitter and the receiver for full duplex communication, where the transmitter has an output coupled to the receiver and the receiver has an input coupled to the antenna;a notch filter comprised of one or more integrated capacitors, the notch filter disposed between the antenna and the receiver, where the notch filter is configured to be tuned by varying one or more capacitance values of the one or more integrated capacitors in the notch filter to select the transmitter channel for rejection by the notch filter, at least one of the one or more integrated capacitors comprising Barium Strontium Titanate (BST) ceramic integrated capacitors that are each tuneable by application ...

Подробнее
Номер записи: 61
30-01-2014 дата публикации

TRANSCEIVER FILTER AND TUNING

Номер: US20140029481A1
Автор: Manku Tajinder, MOTI Zohaib
Принадлежит: BlackBerry Limited

A radio transceiver including a transmitter and a receiver. A filter coupled to an output of the transmitter, the filter has one or more inductors and one or more capacitors, where the filter is tuned by varying one or more capacitance values of the one or more capacitors in the filter to tune the filter. The one or more capacitors are Barium Strontium Titanate (BST) ceramic integrated capacitors that are each tuned by application of a bias voltage thereto. A filter tuner circuit is configured to apply the bias voltage to the one or more capacitors, where the bias voltage is initially established as a stored initial value, and where the bias voltage is refined by a proportional-integral-derivative (PID) controller configured to optimize a power within the transceiver. This abstract is not to be considered limiting since various implementations may incorporate more, fewer or different elements. 1. A radio transceiver , comprising:a transmitter and a receiver;a filter coupled to an output of the transmitter, the filter comprised of one or more integrated capacitors, where the filter is tuned by varying one or more capacitance values of the one or more integrated capacitors in the filter to tune the filter, at least one of the one or more integrated capacitors comprise Barium Strontium Titanate (BST) ceramic integrated capacitors that are each tuneable by application of a bias voltage thereto;a filter tuner circuit that is configured to apply the bias voltage to the one or more integrated capacitors, where the bias voltage is initially established as a stored initial value; anda proportional-integral-derivative (PID) controller configured to refine the bias voltage to optimize a power within the transceiver.2. The radio transceiver according to claim 1 , where the filter comprises a notch filter coupled between a transmitter output and a receiver input of the transceiver that blocks transmitter power from entering the receiver.3. The radio transceiver according to ...

Подробнее
Номер записи: 62
06-02-2014 дата публикации

MOBILE WIRELESS COMMUNICATIONS DEVICE WITH LNA FRONT END CIRCUIT AND RELATED METHODS

Номер: US20140038532A1
Автор: GEORGE Liviu, Hughes Simon Andrew, Little Christopher Robert, Manku Tajinder
Принадлежит: RESEARCH IN MOTION LIMITED

A mobile wireless communications device may include an antenna, LTE RF differential inputs, and a front end circuit. The front end circuit may include band pass filters coupled to the antenna, LNAs coupled respectively to the band pass filters, and RF switching circuits. Each RF switching circuit may be respectively coupled between each LNA and a pair of LTE RF differential inputs and configured to switch to one or both of the pair of LTE RF differential inputs. 1. A mobile wireless communications device comprising:an antenna;a plurality of Long Term Evolution (LTE) radio frequency (RF) differential inputs; and a plurality of band pass filters coupled to said antenna,', 'a plurality of LNAs coupled respectively to said plurality of band pass filters, and', 'a plurality of RF switching circuits, each RF switching circuit respectively coupled between each LNA and a pair of LTE RF differential inputs and configured to switch to one or both of said pair of LTE RF differential inputs., 'a front end circuit comprising'}2. The mobile wireless communications device of wherein said plurality of LTE RF differential inputs comprises:a group of low band LTE RF differential inputs;a group of mid band LTE RF differential inputs; anda group of high band LTE RF differential inputs.3. The mobile wireless communications device of further comprising a controller configured to operate said plurality of RF switching circuits in a carrier aggregation mode.4. The mobile wireless communications device of wherein said controller is configured to operate based upon a Mobile Industry Processor Interface (MIPI).5. The mobile wireless communications device of wherein said front end circuit comprises a plurality of RF splitters respectively coupled between said plurality of LNAs and said plurality of RF switching circuits.6. The mobile wireless communications device of wherein each RF switching circuit comprises a pair of single-pole claim 5 , double-throw switches coupled to a respective one of ...

Подробнее
Номер записи: 63
06-03-2014 дата публикации

COSMETIC COMPOSITIONS COMPRISING EPA AND SALICYLIC ACID AND METHODS OF MAKING AND USING SAME

Номер: US20140066507A1
Автор: Climax John, Coughlan David, Manku Mehar
Принадлежит: DIGNITY SCIENCES LIMITED

The present disclosure is directed generally to cosmetic compositions comprising EPA free acid and salicylic acid. In some embodiments, the cosmetic compositions have a cosmetically acceptable odor. 1. A topical composition comprising eicosapentaenoic acid and salicylic acid , wherein the purity of the eicosapentaenoic acid is at least 95% by weight eicosapentaenoic acid in its free acid form.2. The composition of further comprising gamma-linolenic acid in the free acid form.36-. (canceled)7. The composition of claim 1 , further comprising ascorbyl palmitate.8. The composition of claim 7 , further comprising NaOH.9. The composition of claim 1 , comprising ≦5 weight % eicosapentaenoic free acid claim 1 , by weight of the composition.10. The composition of claim 9 , comprising about 0.5 weight % to about 4.08 weight % eicosapentaenoic free acid.11. The composition of claim 2 , wherein the purity of the gamma-linolenic acid is at least 70% by weight gamma-linolenic free acid.12. The composition of claim 2 , wherein the weight ratio of eicosapentaenoic free acid to gamma-linolenic free acid is about 8:1 to about 2:1.13. The composition of claim 12 , wherein the weight ratio of eicosapentaenoic free acid to gamma-linolenic free acid is about 4:1.14. The composition of claim 2 , comprising about 0.1 weight % to about 3 weight % gamma-linolenic free acid claim 2 , by weight of the composition.15. The composition of comprising about 0.1 weight % to about 5 weight % salicylic acid claim 1 , by weight of the composition.16. The composition of that is free of unpleasant odor.17. A topical composition devoid of unpleasant odor comprising:eicosapentaenoic free acid;gamma-linolenic free acid; andsalicylic acid,wherein the composition has a weight ratio of eicosapentaenoic free acid to gamma linolenic free acid of about 8:1 to about 4:1; andthe eicosapentaenoic free acid and the gamma linolenic free acid are present in a combined amount not greater than 5 weight % of the ...

Подробнее
Номер записи: 64
06-03-2014 дата публикации

COSMETIC COMPOSITIONS COMPRISING EPA AND GLA AND METHODS OF MAKING AND USING SAME

Номер: US20140066509A1
Автор: Climax John, Coughlan David, Manku Mehar
Принадлежит: DIGNITY SCIENCES LIMITED

The present disclosure is directed generally to cosmetic compositions comprising EPA free acid and GLA free acid. In some embodiments, the cosmetic compositions have a cosmetically acceptable odor. 1. A cosmetic composition comprising eicosapentaenoic free acid; gamma-linolenic free acid; and one or more cosmetically acceptable excipients , wherein the eicosapentaenoic free acid and the gamma-linolenic free acid are present in a weight ratio of about 2:1 to about 8:1.2. The composition of claim 1 , wherein the excipients are selected from the group consisting of: solvents claim 1 , sequestrants claim 1 , humectants claim 1 , thickening agents claim 1 , emulsifiers claim 1 , emollients claim 1 , adsorbing agents claim 1 , preservatives claim 1 , fragrances claim 1 , antioxidants claim 1 , pH modifiers claim 1 , texturizing agents claim 1 , and combinations thereof.3. The composition of claim 1 , wherein the excipients comprise water claim 1 , Trilon B (Disodium EDTA) claim 1 , Glycerine Veg. PH EUR 99.5% (Glycerin) claim 1 , Cosmedia SP (sodium polyacrylate) claim 1 , Lincol BAS (C12-15 alkyl benzoate) claim 1 , Lincol SN (cetearyl isononanoate) claim 1 , Burro Di KARITE (butyrospermum parkii butter) claim 1 , Euxyl PE 9010 (phenoxyethanol & ethylhexylglycerin) claim 1 , Profumo Fiori D'acqua 85328 claim 1 , Lipochroman (dimethylmethoxy chromanol) claim 1 , Ascorbyl palmitate claim 1 , Imwitor 372P (glyceryl stearate citrate) claim 1 , Cutina GMS/Bergabest GS40/Lincol GMS (glyceryl stearate) claim 1 , Lanette 22/Vegarol 22/Akest AB/Nafol 1822C (behenyl alcohol) claim 1 , Sodium hydroxide and Dry-Flo PC (aluminum starch octenylsuccinate).4. The composition of claim 1 , wherein the eicosapentaenoic free acid is present in an amount of about 0.5 wt. % to about 8 wt. % claim 1 , about 0.8 wt. % to about 4 wt. % claim 1 , about 0.815 wt. % claim 1 , about 1.631 wt. % claim 1 , or about 4.080 wt. %.5. The composition of claim 1 , wherein the gamma linolenic free acid is ...

Подробнее
Номер записи: 65
20-03-2014 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20140080909A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of treating high triglycerides in a subject receiving statin therapy comprising , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1100 mg to about 1200 mg of eicosapentaenoic acid; (b) docosahexaenoic acid , and (c) docosapentaenoic acid , wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids present in the composition.2. The method of wherein the composition is present in one or more dosage units.3. The method of wherein the dosage units comprise capsules.4. A method of treating high triglycerides in a subject receiving statin therapy comprising claim 2 , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1700 mg to about 1800 mg of eicosapentaenoic acid; (b) docosahexaenoic acid claim 2 , and (c) docosapentaenoic acid claim 2 , wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids in the composition.5. The method of wherein the composition is present in one or more dosage units.6. The method of wherein the one or more dosage units comprise capsules.7. A method of treating high triglycerides in a subject receiving statin therapy comprising claim 5 , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) ...

Подробнее
Номер записи: 66
27-03-2014 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20140088194A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1100 mg to about 1200 mg of eicosapentaenoic acid; (b) docosahexaenoic acid , and (c) docosapentaenoic acid , wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids present in the composition.2. The method of wherein the composition is present in one or more dosage units.3. The method of wherein the dosage units comprise capsules.4. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising claim 2 , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising omega-3 fatty acids including: (a) about 1700 mg to about 1800 mg of eicosapentaenoic acid; (b) docosahexaenoic acid claim 2 , and (c) docosapentaenoic acid claim 2 , wherein the docosahexaenoic acid comprises not more than about 20% by weight of fatty acids in the composition and the docosapentaenoic acid comprises not more than about 7% by weight of fatty acids in the composition.5. The method of wherein the composition is present in one or more dosage units.6. The method of wherein the one or more dosage units comprise capsules.7. A method of lowering triglycerides in a subject with triglycerides of at least 500 mg/dl comprising claim 5 , administering to the subject daily for a period effective to reduce triglycerides in the subject a pharmaceutical composition comprising ...

Подробнее
Номер записи: 67
07-01-2021 дата публикации

METHODS OF TREATING MIXED DYSLIPIDEMIA

Номер: US20210000779A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A method of reducing triglyceride levels in a subject on an anticoagulant/antiplatelet/thrombolytic therapy , having triglyceride levels of at least about 500 mg/dl , and having atrial fibrillation , the method comprising to the subject about 4 g of ethyl icosapentate per day.2. The method of claim 1 , wherein the subject is on statin therapy.3. The method of claim 1 , wherein the subject has a baseline LDL-C level of about 40 mg/dL to about 100 mg/dL.4. The method of claim 1 , wherein the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.5. The method of claim 4 , wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules.6. The method of claim 1 , wherein the subject is administered the icosapent ethyl for a period of at least about 2 years. This application is a continuation of U.S. patent application Ser. No. 16/709,492 filed Dec. 10, 2019, which is a continuation of U.S. patent application Ser. No. 16/179,763 filed Nov. 2, 2018, which is a continuation of U.S. patent application Ser. No. 15/273,430 filed on Sep. 22, 2016 (now U.S. Pat. No. 10,220,013), which is a continuation of U.S. patent application Ser. No. 14/704,329 filed on May 5, 2015 (now U.S. Pat. No. 9,855,237), which is a continuation of U.S. patent application Ser. No. 14/175,602 filed Feb. 7, 2014 (now U.S. Pat. No. 9,056,088), which is a continuation of U.S. patent application Ser. No. 13/898,447 filed on May 20, 2013 (now U.S. Pat. No. 8,691,871), which is a continuation of U.S. patent application Ser. No. 13/540,319 filed on Jul. 2, 2012 (now U.S. Pat. No. 8,618,166), which is a continuation of U.S. patent application Ser. No. 13/417,899 filed on Mar. 12, 2012 (now U.S. Pat. No. 8,563,608), which is a continuation of U.S ...

Подробнее
Номер записи: 68
02-01-2020 дата публикации

STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME

Номер: US20200000759A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A pharmaceutical composition , comprising: omega-3 fatty acids in free acid form including (a) eicosapentaenoic acid in an amount selected from about 925 mg , about 950 mg and about 975 mg; (b) docosapentaenoic acid in an amount of about 5% , by weight of total fatty acids.2. The pharmaceutical composition of claim 1 , wherein the eicosapentaenoic acid is present in an amount of about 925 mg.3. The pharmaceutical composition of claim 1 , wherein the eicosapentaenoic acid is present in an amount of about 950 mg.4. The pharmaceutical composition of claim 1 , wherein the eicosapentaenoic acid is present in an amount of about 975 mg.5. The composition of claim 3 , wherein the composition is present in one or more dosage units.6. The composition of claim 5 , wherein the dosage units comprise capsules.7. A method of reducing triglycerides in a subject in need thereof comprising claim 6 , administering to the subject daily a composition of .8. The method of claim 7 , wherein the subject has very high serum triglycerides. This application is a continuation of U.S. application Ser. No. 15/996,901 filed Jun. 4, 2018 (now allowed), which is a continuation of U.S. application Ser. No. 15/415,468 filed Jan. 25, 2017 (now U.S. Pat. No. 10,010,517), which is a continuation of U.S. application Ser. No. 15/092,391 filed Apr. 6, 2016 (now U.S. Pat. No. 9,585,856), which is a continuation of U.S. application Ser. No. 14/709,937 filed May 12, 2015, which is a continuation of Ser. No. 14/259,724 filed Apr. 23, 2014 (now U.S. Pat. No. 9,072,715), which is a continuation of U.S. application Ser. No. 14/084,887 filed Nov. 20, 2013 (now U.S. Pat. No. 9,060,982), which is a continuation of U.S. application Ser. No. 13/685,291 filed Nov. 26, 2012 (now U.S. Pat. No. 8,613,945), which is a ...

Подробнее
Номер записи: 69
08-01-2015 дата публикации

TRANSMISSION APPARATUS FOR A WIRELESS DEVICE USING DELTA-SIGMA MODULATION

Номер: US20150009018A1
Автор: Manku Tajinder
Принадлежит:

A transmission apparatus for a wireless device, comprising: an antenna for receiving an original signal and for backscattering a modulated signal containing information from the wireless device; a variable impedance coupled to the antenna, the variable impedance having an impedance value; a delta-sigma modulator coupled to the variable impedance for modulating the impedance value, and thereby a backscattering coefficient for the antenna, in accordance with the information to generate the modulated signal; and, a decoder coupled to the delta-sigma modulator for generating the impedance value from the information. 1. A transmission apparatus for a wireless device , comprising:an antenna for receiving an original signal and for backscattering a modulated signal containing information from the wireless device;a variable impedance coupled to the antenna, the variable impedance having an impedance value;a delta-sigma modulator coupled to the variable impedance for modulating the impedance value, and thereby a backscattering coefficient for the antenna, in accordance with the information to generate the modulated signal; and,a decoder coupled to the delta-sigma modulator for generating the impedance value from the information.2. The transmission apparatus of wherein the variable impedance is coupled in series with the antenna.3. The transmission apparatus of wherein the wireless device is powered by energy from the original signal.4. The transmission apparatus of wherein the variable impedance includes an array of impedances and respective switches.5. The transmission apparatus of wherein the decoder includes a backscattering coefficient to impedance value decoder.6. The transmission apparatus of wherein the information is an N-bit digital waveform.7. The transmission apparatus of wherein the N-bit digital waveform is applied to the decoder and then to the delta-sigma modulator to produce a control signal for the variable impedance that is related to the N-bit digital ...

Подробнее
Номер записи: 70
11-01-2018 дата публикации

COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF USING THE SAME

Номер: US20180008567A1
Автор: Climax John, Coughlan David, Manku Mehar
Принадлежит:

The present disclosure relates to the compositions, formulations and methods of treating or preventing diseases mediated by peroxisome proliferator-activated receptors (PPARs) by administration of 15-HEPE. 1. A method for treating or preventing a disease mediated by peroxisome proliferator-activated receptors (PPARs) in a subject comprising , administering to the subject pharmaceutical composition comprising 15-HEPE to treat or prevent the disease in the subject.2. The method of claim 1 , wherein the disease is selected from impaired insulin sensitivity claim 1 , psoriasis claim 1 , cancer claim 1 , fibrosis claim 1 , melanoma claim 1 , neurodegenerative disorders claim 1 , Huntington's disease claim 1 , inflammatory diseases claim 1 , adipocyte differentiation claim 1 , fertility or reproduction diseases claim 1 , pain claim 1 , and obesity.3. The method of claim 1 , wherein the 15-HEPE is present in the composition in an amount from about 50 mg to about 1000 mg.4. The method of claim 1 , wherein the 15-HEPE represents at least about 90% of all fatty acids present in the composition.5. The method of claim 1 , wherein the 15-HEPE represents substantially all fatty acids present in the composition.6. The method of claim 1 , wherein the 15-HEPE represents all fatty acids present in the composition.7. The method of wherein the composition is free of any other omega-3 fatty acids.8. The method of claim 1 , wherein the administering step includes administering the pharmaceutical composition to the human subject about 1 to about 4 times per day.9. The method of claim 1 , wherein the pharmaceutical composition comprises an orally deliverable capsule.10. The method of claim 1 , wherein the human subject has a predisposition to and/or a diagnosis of the liver disease.11. A method for treating or preventing a disease mediated by peroxisome proliferator-activated receptors (PPARs) in a subject comprising claim 1 , administering to the subject pharmaceutical composition ...

Подробнее
Номер записи: 71
12-01-2017 дата публикации

RADIO FREQUENCY CAMERA SYSTEM

Номер: US20170013207A1
Автор: Manku Tajinder
Принадлежит:

In some aspects, a radio-frequency (RF) camera system includes a sensor assembly and a data processing system. The sensor assembly includes sensors supported at respective sensor locations. Each sensor is supported at one of the sensor locations and configured to detect RF signals from a field of view defined by the sensor assembly. Each sensor is configured to identify parameters of the RF signals detected by the sensor. The data processing system is configured to receive the parameters identified by the sensors and generate a graphical representation of the field of view based on the parameters. 1. A radio-frequency (RF) camera system comprising: a radio subsystem configured to detect RF signals from a field of view defined by the sensor assembly unit; and', 'a processor subsystem configured to process the RF signals detected by the radio subsystem to identify parameters of the RF signals, the parameters comprising phases of the RF signals; and, 'a sensor assembly unit comprising sensors supported at respective sensor locations, each sensor being supported at one of the sensor locations and comprising receive the parameters identified by the sensors; and', 'generate a graphical representation of the field of view based on the phases., 'a data processing system configured to2. (canceled)3. The RF camera system of claim 1 , wherein the processor subsystem of each sensor is configured to identify amplitudes of the RF signals detected by the sensor claim 1 , and the data processing system is configured to generate the graphical representation of the field of view based on the phases and amplitudes.4. The RF camera system of claim 1 , wherein the sensor assembly unit comprises a support structure that supports the sensors at their respective sensor locations claim 1 , and the sensor locations define a planar sensor domain.5. The RF camera system of claim 1 , wherein the sensor locations define a three-dimensional sensor domain.6. The RF camera system of claim 1 , ...

Подробнее
Номер записи: 72
19-01-2017 дата публикации

METHODS OF TREATING MIXED DYSLIPIDEMIA

Номер: US20170014366A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A pharmaceutical composition comprising eicosapentaenoic acid (EPA) or a derivative of EPA , docosahexaenoic acid (DHA) or a derivative of DHA , and at least one surfactant.2. The pharmaceutical composition of further comprising at least one additional fatty acid selected from the group consisting of linolenic acid (LA) claim 1 , derivative of LA claim 1 , arachidonic acid (AA) claim 1 , derivative of AA claim 1 , alpha-linolenic acid (ALA) claim 1 , derivative of ALA claim 1 , stearadonic acid (STA) claim 1 , derivative of STA claim 1 , eicosatrienoic acid (ETA) claim 1 , derivative of ETA claim 1 , docosapentaenoic acid (DPA) claim 1 , derivative of DPA claim 1 , or combinations thereof.3. The pharmaceutical composition of wherein the derivative of EPA is ethyl-EPA.4. The pharmaceutical composition of wherein the derivative of DHA is ethyl-DHA.5. The pharmaceutical composition of comprising a mixture of EPA or a derivative of EPA and DHA or a derivative of DHA claim 1 , in a ratio of EPA or a derivative of EPA to DHA or a derivative of DHA from greater than about 2:1 to about 19:1 claim 1 , wherein the EPA or a derivative of EPA and DHA or a derivative of DHA in combination comprise more than about 50% by weight of total fatty acids present in the pharmaceutical composition.6. The pharmaceutical composition of comprising a mixture of EPA or a derivative of EPA and DHA or a derivative of DHA claim 1 , wherein the EPA or a derivative of EPA comprises about 50% by weight of total fatty acids present in the pharmaceutical composition and the DHA or a derivative of DHA comprises about 20% by weight of total fatty acids present in the pharmaceutical composition.7. The pharmaceutical composition of wherein the at least one surfactant is selected from the group consisting a polysorbate claim 1 , a poloxamer claim 1 , or combinations thereof.8. The ...

Подробнее
Номер записи: 73
26-01-2017 дата публикации

Compositions Comprising 15-HEPE and Methods of Treating or Preventing Cancer and Neurologic Disease

Номер: US20170020836A1
Автор: Climax John, Coughlan David, Manku Mehar
Принадлежит:

The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing cancer and neurological diseases in a subject in need thereof. 1. A method of treating and/or preventing cancer in a subject in need thereof , the method comprising administering to the subject 15-HEPE or a composition comprising 15-HEPE.2. The method of claim 1 , wherein the 15-HEPE is in free acid form.3. The method of claim 1 , wherein the 15-HEPE is in esterified form.4. The method of claim 3 , wherein the esterified form is an alkyl ester form.5. The method of claim 4 , wherein the esterified form is ethyl ester.6. The method of claim 3 , wherein the esterified form is a triglyceride form.7. The method of claim 1 , wherein the cancer is selected from carcinoma claim 1 , CNS cancer claim 1 , liver cancer claim 1 , hepatocellular carcinoma claim 1 , skin cancer claim 1 , prostate cancer claim 1 , breast cancer claim 1 , carcinoma claim 1 , sarcoma claim 1 , leukaemia claim 1 , lymphoma-myeloma and CNS cancer.8. The method of claim 1 , wherein the 15-HEPE comprises claim 1 , consists essentially of claim 1 , or consists of 15(S)-HEPE or a derivative thereof.9. The method of claim 1 , wherein the 15-HEPE comprises claim 1 , consists essentially of claim 1 , or consists of 15(R)-HEPE or a derivative thereof.10. A method of treating and/or preventing a CNS disease in a subject in need thereof claim 1 , the method comprising administering to the subject 15-HEPE or a composition comprising 15-HEPE.11. The method of claim 10 , wherein the 15-HEPE is in free acid form.12. The method of claim 10 , wherein the 15-HEPE is in esterified form.13. The method of claim 12 , wherein the esterified form is an alkyl ester form.14. The method of claim 13 , wherein the esterified form is ethyl ester.15. The method of claim 12 , wherein the esterified form is a triglyceride form.16. The method of claim 10 , wherein the CNS disease is selected from catalepsy claim 10 ...

Подробнее
Номер записи: 74
10-02-2022 дата публикации

SYSTEMS AND METHODS FOR MICROCOLONY GROWTH AND MICROBIAL CELL CHARACTERIZATION

Номер: US20220042066A1
Автор: Alavie Tino, ASADISHEKARI MARYAM, KHIMCHENKO ANNA, Khine Aye Aye, Leonard Stephen Wesley, Maaskant Robert, MANKU SUKHDEV, PARMAR VILCY, SAMIEI ALALEH, Talebpour Samad, YASOTHARAN Sanjesh
Принадлежит:

An integrated fluidic device is employed to perform microbial cell separation, in situ microcolony growth, and optional identification and antimicrobial susceptibility testing. While the integrated fluidic device is maintained in a closed state, microbial cell separation is performed to provide a microbial cell suspension that is contacted with a solid phase growth medium. A liquid component of the suspension is removed, thereby retaining microbial cells on the growth medium for incubation, growth, and subsequent harvesting and characterization. In some embodiments, antimicrobial susceptibility testing is performed by contacting growth media with a solid support having an antimicrobial agent provided thereon, such that the antimicrobial agent diffuses into a subregion of the growth medium that is accessible through an aperture surrounded, at least in part, by the solid support. Microbial cells retained on the surface of the subregion may be assessed for growth or inhibition in the presence of the antimicrobial agent. 179-. (canceled)80. A method of processing a sample suspected of containing microbial cells , the method comprising:contacting a suspension of viable microbial cells with a solid phase growth medium under conditions suitable for promoting growth of the viable microbial cells;detecting a presence of a colony on the solid phase growth medium, the colony having a diameter of less than 100 microns;optically interrogating the colony to identify a microbial cell class associated with the colony;employing the microbial cell class to determine when the colony is expected to contain a sufficient quantity of microbial cells to perform antimicrobial susceptibility testing;after the colony has grown to contain the sufficient quantity of microbial cells for antimicrobial susceptibility testing, harvesting microbial cells from the colony; andemploying the harvested microbial cells to perform antimicrobial susceptibility testing.81. The method according to wherein the ...

Подробнее
Номер записи: 75
08-02-2018 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND USE OF SAME

Номер: US20180036272A1
Автор: Climax John, Coughlan David, Dunne James, Manku Mehar
Принадлежит:

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders. 130-. (canceled)31. A method of treating atopic dermatitis in a subject in need thereof , the method comprising orally administering to the subject at least 200 mg per day of a pharmaceutical composition comprising dihomo gamma linolenic acid , eicosatetraenoic acid , eicosatrienoic acid , oleic acid , linoleic acid and eicosadienoic acid encapsulated in a capsule shell wherein the composition comprises at least about 80% dihomo gamma linolenic acid by weight of total fatty acids.32. The method of wherein about 200 mg to about 4 g of the pharmaceutical composition is administered to the subject per day.33. The method of wherein the composition is present in one or more capsules each comprising a capsule shell.34. The method of wherein the capsule shell comprises gelatin and glycerol.35. The method of wherein about 200 mg to about 1 g of the composition is encapsulated in each of said one or more capsules.36. The method of wherein about 500 mg to about 1 g of the composition is encapsulated in each of said one or more capsules.37. The method of wherein the capsule shell comprises lime bone gelatin and one or more of: glycerol claim 33 , purified water claim 33 , titanium dioxide claim 33 , medium chain triglycerides and/or lecithin.38. The method of wherein the composition comprises not more than 5% claim 31 , by weight of total fatty acids claim 31 , of any individual fatty acid other than dihomo gamma linolenic acid.39. The method of wherein the composition comprises not more than 5% claim 36 , by weight of total fatty acids claim 36 , of any individual fatty acid other than dihomo gamma linolenic acid.40. A method of treating atopic dermatitis in a subject in need thereof claim 36 , the method comprising orally administering to the subject about 500 mg to about 2 g per day of a pharmaceutical ...

Подробнее
Номер записи: 76
07-02-2019 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20190038590A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of lowering high-sensitivity C-reactive protein in a subject in need thereof , the method comprising:determining a baseline high-sensitivity C-reactive protein level in the subject, the subject having a triglyceride level of at least 500 mg/dl; andadministering to the subject daily (a) about 4 g of a pharmaceutical composition comprising at least 96% pure ethyl-EPA and (b) a statin for a period of at least 12 weeks to effect a reduction in high-sensitivity C-reactive protein of at least about 20% compared to the baseline.2. The method of wherein the pharmaceutical composition contains substantially no DHA or derivative thereof.3. The method of wherein the subject has a triglyceride level of 500 mg/dl to about 2000 mg/dl.4. The method of wherein the subject has a triglyceride level of 750 mg/dl to about 2000 mg/dl.5. The method of wherein the subject is a diabetic.6. The method of wherein said administration is continued for a period greater than 12 weeks.7. The method of wherein the step of administering effects a reduction in high-sensitivity C-reactive protein of at least about 40% compared to the baseline.8. The method of wherein the step of administering effects a reduction in high sensitivity C-reactive protein of at least about 20% compared to a subject having baseline triglycerides of at least 500 mg/dl who receives statin therapy but not the pharmaceutical composition.9. The method of claim 1 , further comprising determining a baseline fasting triglycerides in the subject claim 1 , and administering to the subject about 4 g of the pharmaceutical composition and the statin daily for the period of at least 12 weeks to effect a reduction ...

Подробнее
Номер записи: 77
18-02-2021 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20210046036A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 13.-. (canceled)4. A method of reducing triglycerides in a subject having a fasting baseline triglyceride level of at least about 700 mg/dl , atrial fibrillation , and on a statin therapy , the method comprising administering to the subject about 4 g of ethyl eicosapentaenoate per day.5. The method of claim 4 , wherein the ethyl eicosapentaenoate is present in a pharmaceutical composition and the ethyl eicosapentaenoate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.6. The method of claim 5 , wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules.7. The method of claim 4 , wherein the subject has a baseline LDL-C level of about 40 mg/dL to about 100 mg/dL.8. The method of claim 4 , wherein the subject is diabetic.9. The method of claim 4 , wherein the subject exhibits at least about a 10% 4reduction in fasting triglycerides compared to a baseline triglyceride level.10. The method of claim 9 , wherein the subject exhibits no statistically significant increase in LDL-C compared to a LDL-C level prior to initial administration of the ethyl eicosapentaenoate.11. The method of claim 5 , wherein the statin therapy is a stable statin therapy.12. The method of claim 5 , wherein the subject is administered the ethyl eicosapentaenoate for at least about 12 weeks.13. The method of claim 5 , further comprising reducing a risk of stroke claim 5 , myocardial infarction claim 5 , or both in the subject. This application is a continuation of U.S. application Ser. No. 16/854,757 filed Apr. 21, 2020, which is a continuation of U.S. application Ser. No. 16/029,198 filed Jul. 6, 2018, which is a ...

Подробнее
Номер записи: 78
15-02-2018 дата публикации

METHODS OF TREATING MIXED DYSLIPIDEMIA

Номер: US20180042880A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 124-. (canceled)25. A method of reducing triglycerides and LDL-C in a subject on stable rosuvastatin therapy having baseline fasting triglycerides of 200 mg/dl to about 500 mg/dl comprising , administering daily to the subject for a period of at least about 12 weeks about 4 g of fatty acids composed of at least about 96% ethyl eicosapentaenoate , by weight of all fatty acids , and not more than about 3% docosahexaenoic acid or its esters by weight of all fatty acids , to effect a reduction in triglycerides and LDL-C in the subject.26. The method of claim 25 , wherein the subject has a baseline LDL-C level of about 40 mg/dl to about 115 mg/dl.27. The method of claim 25 , comprising administering said fatty acids to the subject daily for the period to effect a reduction in LDL-C of at least about 10% compared to placebo control.28. The method of claim 27 , comprising administering fatty acids to the subject daily for the period to effect a reduction in triglycerides of at least about 15% compared to placebo control.29. The method of claim 25 , wherein the fatty acids are administered in 4 capsules claim 25 , each capsule comprising about 900 mg to about 1.2 g of ethyl eicosapentaenoate.30. The method of wherein the rosuvastatin and at least a portion of the fatty acids are co-administered in different dosage units.31. A method of reducing triglycerides and LDL-C in a subject on stable rosuvastatin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl comprising claim 25 , administering to the subject daily for a period of at least about 12 weeks 4 capsules claim 25 , each capsule comprising about 900 mg to about 1.2 g of ethyl eicosapentaenoate and not more than about 3% docosahexaenoic acid or its esters claim 25 , by weight of all fatty acids present claim 25 , to effect a reduction in triglycerides and LDL-C in the ...

Подробнее
Номер записи: 79
15-02-2018 дата публикации

COMPOSITIONS AND METHODS FOR LOWERING LEVELS OF HIGH-SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) IN A SUBJECT

Номер: US20180042883A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In some embodiments, the method comprises lowering high sensitivity CRP (hs-CRP) levels in a subject including, for example, a subject with a HbAvalue of about 5.00%-8.50% or at least about 6.8%. 1. A method of reducing an hsCRP level in a subject in need thereof , the method comprising: (a) identifying a subject having a fasting baseline triglyceride level of about 200 mg/dl to about 1500 mg/dl , and (b) administering to the subject about 2 g to about 4 g per day of a pharmaceutical composition comprising at least about 90% , by weight of all fatty acids present , ethyl eicosapentaenoate , for a period effective to reduce the hsCRP level in the subject.2. The method of wherein the composition is administered to the subject 1 to 4 times per day.3. The method of wherein the composition is present in a capsule.4. The method of wherein the subject is not on concomitant lipid-altering therapy.5. The method of further comprising a step of measuring a baseline lipid profile in the subject prior to administering the pharmaceutical composition to said subject.6. The method of claim 1 , wherein the period is about 12 weeks and is effective to: (a) reduce triglyceride levels compared to baseline; (b) reduce ICAM-1 level compared to baseline; (c) reduce ox-LDL level compared to baseline; (d) reduce IL-6 level compared to baseline; and/or (e) reduce hsCRP level compared to baseline.7. The method of wherein the subject exhibits one or more of: (a) a placebo-adjusted reduction in triglyceride level of at least about 5% as compared to baseline; (b) a placebo-adjusted increase in ICAM-1 level of less than 10% or a placebo-adjusted reduction in ICAM-1 level of at least about 1% as compared to ...

Подробнее
Номер записи: 80
19-02-2015 дата публикации

Method and system for identifying and finding a range of an object

Номер: US20150048966A1
Автор: Tajinder Manku
Принадлежит: Tag Comm Inc

A method for identifying and ranging a wireless device, comprising: transmitting an original radar signal from a detecting system; in response to the original radar signal, receiving a modulated radar signal at the detecting system, the modulated radar signal being backscattered from an antenna of the wireless device and containing information pertaining to the wireless device, and the modulated radar signal being a frequency offset version of the original radar signal; and, using a processor at the detecting system, determining an identity and a range of the wireless device from the modulated radar signal.

Подробнее
Номер записи: 81
03-03-2022 дата публикации

HANDLING OUT-OF-ORDER DATA DURING STREAM PROCESSING AND PERSISTING IT IN A TEMPORAL GRAPH DATABASE

Номер: US20220067099A1
Автор: NARAYANAN Bhalaji, Nethi Ramesh, Raghavendra Arun Kumar, Simhadri Mehar
Принадлежит:

The present technology addresses deficiencies associated with common practices for handling out of order data in a streaming data database. An aspect of the present technology is avoid storing out of order data in a snapshot but just store the out of order data as additional data linked to the temporal graph. The present technology receives out of order data and records a modification time for the data and a next modification time for the data that equals a timestamp of data previously stored in the database. If there is also data in the database for a time earlier than the timestamp of the out of order data, the earlier data is adjusted so that its next modification time matches the timestamp of the out of order data. 1. A non-transitory computer readable medium comprising instructions stored thereon , the instructions are effective to cause at least one processor to:receive new data pertaining to a graph element in a temporal graph, the temporal graph comprising different types of graph elements including vertices and edges, for storing information of a computer network;determine that the temporal graph already stores second data for the graph element having a timestamp denoting a second time, wherein the new data was recorded at a first time that is the same or earlier than the second time; andinsert the new data into the temporal graph by recording data for the graph element in a temporal graph database with a timestamp for the new data denoting the first time and a next modification time for the new data that denotes the second time.2. The non-transitory computer readable medium of claim 1 , comprising further instructions that are effective to cause the at least one processor to:prior to the insertion of the new data into the temporal graph, determine that the temporal graph already stores third data for the graph element having a timestamp for the third data denoting a third time and that has a next modification time for the third data that denotes the second ...

Подробнее
Номер записи: 82
03-03-2022 дата публикации

Controlling Device Participation in Wireless Sensing Systems

Номер: US20220068099A1
Автор: Beg Christopher, Manku Tajinder, OMER Mohammad
Принадлежит: Cognitive Systems Corp.

In a general aspect, motion is detected using wireless signals. In an example, a method includes receiving, at a wireless communication device, requests for the wireless communication device to transmit wireless signals, the requests initiated by a wireless sensing system. The method further includes transmitting a series of wireless signals from the wireless communication device in response to the requests, and detecting, at the wireless communication device, a trigger event after transmitting the series of wireless signals. The method additionally includes updating, by the wireless communication device, a state of the wireless communication device based on the trigger event, the updated state indicating that the wireless communication device is not enabled to transmit wireless signals in response to the requests from the wireless sensing system. The method also includes communicating, by the wireless communication device, the updated state of the wireless communication device to the wireless sensing system.

Подробнее
Номер записи: 83
03-03-2016 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20160058729A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing large vLDL particle concentration in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl comprising administering to the subject about 4 g per day ethyl eicosapentaenoate thereby to produce a reduction in large vLDL particle concentration.2. The method of wherein said reduction is statistically significant.3. The method of wherein administering to the subject about 4 g per day of ethyl eicosapentaenoate produces a reduction in large vLDL particle concentration by comparison with a baseline large vLDL particle concentration prior to initiation of administration.4. The method of wherein the reduction in large vLDL particle concentration is at least a 2.5% reduction.5. The method of wherein the reduction in large vLDL particle concentration is at least a 10% reduction.6. The method of wherein the reduction in large vLDL particle concentration is at least a 20% reduction.7. The method of wherein the reduction in large vLDL particle concentration is at least about 24% reduction.8. The method of wherein the subject is administered about 3.8 g to about 4 g per day of ethyl eicosapentaenoate.9. The method of wherein the subject is administered ethyl eicosapentaenoate for a period of 12 weeks.10. A method of reducing small LDL particle concentration in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl comprising claim 1 , administering to the subject about 4 g per day of ethyl eicosapentaenoate thereby to produce a reduction in small LDL particle concentration by comparison with a baseline small LDL particle concentration prior to initiation of ...

Подробнее
Номер записи: 84
17-03-2022 дата публикации

METHODS OF TREATING MIXED DYSLIPIDEMIA

Номер: US20220079906A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A pharmaceutical composition comprising a PPAR agonist dispersed in eicosapentaenoic acid , wherein the pharmaceutical composition is present in a capsule.2. The pharmaceutical composition of claim 1 , wherein the eicosapentaenoic acid comprises at least about 80 wt. % of all omega-3 fatty acids in the pharmaceutical composition.3. The pharmaceutical composition of claim 1 , wherein the eicosapentaenoic acid comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition.4. The pharmaceutical composition of claim 1 , wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules.5. The pharmaceutical composition of claim 1 , wherein the eicosapentaenoic acid is ethyl eicosapentaenoate.6. The pharmaceutical composition of claim 1 , wherein the PPAR agonist is selected from the group consisting of fenofibrate claim 1 , bezafibrate claim 1 , ciprofibrate claim 1 , clofibrate claim 1 , gemfibrozil claim 1 , CER-002 claim 1 , rosiglitazone claim 1 , GW501516 claim 1 , RWJ 800025 claim 1 , KD-3010 claim 1 , and combinations thereof7. The pharmaceutical composition of claim 1 , wherein the PPAR agonist is present in an amount of about 0.5 mg to about 120 mg.8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises not more than 10% docosahexaenoic acid (DHA).9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises substantially no DHA.10. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises no DHA. This application is a continuation of U.S. patent application Ser. No. 17/393,213 filed Aug. 3, 2021, which is a continuation of U.S. patent application Ser. No. 17/208,091 filed Mar. 22, 2021, which is a divisional of U.S. patent application Ser. No. 16/709,492 filed Dec. 10, 2019 (now U.S. Pat ...

Подробнее
Номер записи: 85
17-03-2022 дата публикации

METHODS OF TREATING MIXED DYSLIPIDEMIA

Номер: US20220079907A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A pharmaceutical composition comprising a statin suspended in eicosapentaenoic acid (EPA) or derivative thereof , wherein the composition is present in a capsule.2. The pharmaceutical composition of wherein the EPA or derivative thereof comprises ethyl-EPA.3. The composition of wherein the ethyl-EPA comprises at least 95% by weight of all fatty acids or derivatives thereof present in the composition.4. The composition of wherein the statin is selected from lovastatin claim 3 , mevastatin claim 3 , pitavastatin claim 3 , pravastatin claim 3 , rosuvastatin claim 3 , fluvastatin claim 3 , atorvastatin and simvastatin.5. The composition of wherein about 900 mg to about 1 g of ethyl-EPA is present in the capsule.6. The composition of wherein about 1 mg to about 80 mg of a statin is present in the capsule.7. The composition of wherein the statin comprises rosuvastatin and is present in the capsule in an amount of about 5 mg to about 40 mg.8. The composition of wherein the statin is in the form of a tablet. This application is a continuation of U.S. patent application Ser. No. 17/393,213 filed Aug. 3, 2021, which is a continuation of U.S. patent application Ser. No. 17/208,091 filed Mar. 22, 2021, which is a divisional of U.S. patent application Ser. No. 16/709,492 filed Dec. 10, 2019 (now U.S. Pat. No. 10,987,331), which is a continuation of U.S. patent application Ser. No. 16/179,763 filed Nov. 2, 2018 (now U.S. Pat. No. 10,940,131), which is a continuation of U.S. patent application Ser. No. 15/273,430 filed on Sep. 22, 2016 (now U.S. Pat. No. 10,220,013), which is a continuation of U.S. patent application Ser. No. 14/704,329 filed May 5, 2015 (now U.S. Pat. No. 9,855,237), which is a continuation of U.S. patent application Ser. No. 14/175,602 filed Feb. 7, 2014 (now U.S. Pat. No. 9,056,088), which is a continuation of U.S. patent application Ser. No. ...

Подробнее
Номер записи: 86
27-02-2020 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20200061012A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 19-. (canceled)10. A method of reducing small LDL particle concentration in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl and a baseline small LDL particle concentration of about 800 nmol/L to about 1400 nmol/L , comprising , administering to the subject about 4 g per day of ethyl eicosapentaenoate thereby to produce a reduction in small LDL particle concentration by comparison with a baseline small LDL particle concentration prior to initiation of administration , wherein the small LDL particle has a diameter of 18.0-20.5 nm.11. The method of wherein the reduction in small LDL particle concentration is at least a 5% reduction.12. The method of wherein the reduction in small LDL particle concentration is at least a 9% reduction.13. The method of wherein the subject is administered about 3.8 g to about 4 g per day of ethyl eicosapentaenoate.14. The method of wherein the subject is administered ethyl eicosapentaenoate for a period of 12 weeks. Cardiovascular disease is one of the leading causes of death in the United States and most European countries. It is estimated that over 70 million people in the United States alone suffer from a cardiovascular disease or disorder including but not limited to high blood pressure, coronary heart disease, dyslipidemia, congestive heart failure and stroke. A need exists for improved treatments for cardiovascular diseases and disorders.In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related diseases and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a ...

Подробнее
Номер записи: 87
12-03-2015 дата публикации

METHOD AND SYSTEM FOR LOCATING WIRELESS DEVICES WITHIN A LOCAL REGION

Номер: US20150070218A1
Автор: Manku Tajinder
Принадлежит: TAG-COMM INC.

A method for locating wireless devices within a local region, comprising: determining respective global locations of two or more of the wireless devices; determining whether the wireless devices are within the local region by calculating respective distances between the global locations; determining respective ranges between the wireless devices within the local region; and, determining respective relative locations of the wireless devices within the local region by triangulation using the ranges. 1. A method for locating wireless devices within a local region , comprising:determining respective global locations of two or more of the wireless devices;determining whether the wireless devices are within the local region by calculating respective distances between the global locations;determining respective ranges between the wireless devices within the local region; and,determining respective relative locations of the wireless devices within the local region by triangulation using the ranges.2. The method of wherein the determining the respective ranges between the wireless devices within the local region includes: transmitting respective original signals from the wireless devices; in response to the respective original signals claim 1 , receiving respective modulated signals at ones of the wireless devices from others of the wireless devices claim 1 , the modulated signals being backscattered from the others of the wireless devices claim 1 , the modulated signals being frequency offset versions of the original signals; and claim 1 , determining the ranges between the wireless devices from the modulated signals.3. The method of and further comprising measuring respective powers of the modulated signals claim 2 , the powers of the modulated signals being inversely proportional to the ranges between the respective wireless devices to the fourth power.4. The method of wherein the respective original signals are transmitted sequentially from the wireless devices.5. The ...

Подробнее
Номер записи: 88
11-03-2021 дата публикации

METHODS OF TREATING HYPERTRIGLYCERIDEMIA

Номер: US20210069142A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing a low-density lipoprotein (LDL) particle number in a subject in need thereof , comprising measuring a baseline LDL particle number associated with the subject; and thereafter administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day.2. The method of claim 1 , further comprising measuring a baseline lipid profile in the subject prior to administering the pharmaceutical composition to the subject.3. The method of claim 1 , wherein after administration of the pharmaceutical composition claim 1 , the subject experiences a reduction in LDL particle number of at least about 5% compared to baseline.4. The method of claim 1 , wherein the subject is administered 2 g to about 4 g of ethyl eicosapentaenoate per day.5. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject 1 to 4 times per day.6. The method of claim 1 , wherein ethyl eicosapentaenoate represents at least about 90% claim 1 , by weight claim 1 , of all fatty acids in the pharmaceutical composition.7. The method of claim 6 , wherein ethyl eicosapentaenoate represents at least about 95% claim 6 , by weight claim 6 , of all fatty acids in the pharmaceutical composition.8. The method of claim 7 , wherein ethyl eicosapentaenoate represents at least about 96% claim 7 , by weight claim 7 , of all fatty acids in the pharmaceutical composition.9. The method of claim 1 , wherein docosahexaenoic acid and its derivatives represent no more than about 10% claim 1 , by weight claim 1 , of all fatty acids in the pharmaceutical composition.10. The method of claim 9 , wherein ...

Подробнее
Номер записи: 89
07-03-2019 дата публикации

Methods of treating mixed dyslipidemia

Номер: US20190070141A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharmaceuticals Ireland Ltd

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Подробнее
Номер записи: 90
16-03-2017 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND USE OF SAME

Номер: US20170071890A1
Автор: Climax John, Coughlan David, Dunne James, Manku Mehar
Принадлежит:

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders. 1. A method of treating atopic dermatitis in a human subject , the method comprising administering to the subject daily a pharmaceutical composition comprising 600 mg to 5000 mg of dihomo gamma linolenic acid.2. The method of wherein the pharmaceutical composition is present in one or more capsules.3. The method of wherein each of the one or more capsules comprises 500 mg to about 1 g of the pharmaceutical composition.4. The method of wherein two capsules each comprising about 1 g of the pharmaceutical composition are administered to the subject per day.5. The method of wherein four capsules each comprising about 1 g of composition are administered to the subject per day.6. The method of wherein the dihomo gamma linolenic acid comprises at least about 80% by weight of total fatty acids present in the pharmaceutical composition.7. The method of wherein said administering effects an increase in plasma total DGLA of at least about 10% in the subject.8. The method of wherein the pharmaceutical composition further comprises eicosatrienoic acid and eicosadienoic acid.9. A method of treating atopic dermatitis in a human subject claim 1 , the method comprising administering daily to the subject a pharmaceutical composition comprising dihomo gamma linolenic acid claim 1 , eicosatrienoic acid and eicosadienoic acid claim 1 , wherein the dihomo gamma linolenic acid comprises at least about 80% by weight of all fatty acids in the composition and the pharmaceutical composition is administered in an amount effective to deliver 600 mg to 5000 mg of dihomo gamma linolenic acid to the subject per day.10. The method of wherein the composition is present in one or more capsules.11. The method of wherein each of the one or more capsules comprises about 500 mg to about 1 g of the composition.12. The method of wherein ...

Подробнее
Номер записи: 91
05-03-2020 дата публикации

Pharmaceutical compositions comprising dgla and use of same

Номер: US20200069627A1
Автор: David Coughlan, James Dunne, John Climax, Mehar Manku
Принадлежит: DS Biopharma Ltd

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

Подробнее
Номер записи: 92
05-06-2014 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING FATTY ACIDS

Номер: US20140154310A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. 1. A pharmaceutical composition comprising eicosapentaenoic acid (EPA) or a derivative of EPA , docosahexaenoic acid (DHA) or a derivative of DHA , and at least one surfactant.2. The pharmaceutical composition of further comprising at least one additional fatty acid selected from the group consisting of linolenic acid (LA) claim 1 , derivative of LA claim 1 , arachidonic acid (AA) claim 1 , derivative of AA claim 1 , alpha-linolenic acid (ALA) claim 1 , derivative of ALA claim 1 , stearadonic acid (STA) claim 1 , derivative of STA claim 1 , eicosatrienoic acid (ETA) claim 1 , derivative of ETA claim 1 , docosapentaenoic acid (DPA) claim 1 , derivative of DPA claim 1 , or combinations thereof.3. The pharmaceutical composition of wherein the derivative of EPA is ethyl-EPA.4. The pharmaceutical composition of wherein the derivative of DHA is ethyl-DHA.5. The pharmaceutical composition of comprising a mixture of EPA or a derivative of EPA and DHA or a derivative of DHA claim 1 , in a ratio of EPA or a derivative of EPA to DHA or a derivative of DHA from greater than about 2:1 to about 19:1 claim 1 , wherein the EPA or a derivative of EPA and DHA or a derivative of DHA in combination comprise more than about 50% by weight of total fatty acids present in the pharmaceutical composition.6. The pharmaceutical composition of comprising a mixture of EPA or a derivative of EPA and DHA or a derivative of DHA claim 1 , wherein the EPA or a derivative of EPA comprises about 50% by weight of total fatty acids present in the pharmaceutical composition and the DHA or a derivative of DHA comprises about 20% by weight of total fatty acids present in the pharmaceutical composition.7. The pharmaceutical composition of wherein the at least one surfactant is selected from the group consisting a polysorbate claim 1 , a poloxamer claim 1 , or combinations thereof.8. The ...

Подробнее
Номер записи: 93
19-03-2015 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING DHA, EPA, AND/OR GLA AND AN ANTIBIOTIC AGENT AND METHODS OF USE THEREOF

Номер: US20150080329A1
Автор: Climax John, Manku Mehar, Rowe Jonathan
Принадлежит:

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DHA, EPA and/or GLA, used in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin or ocular infection. 1. A pharmaceutical composition comprising:DHA, EPA, or GLA; anda therapeutically effective amount of one or more antibiotic agents.2. The pharmaceutical composition of wherein the antibiotic agent is neomycin.3. A pharmaceutical composition comprising:GLA; anda therapeutically effective amount of one or more antibiotic agents.4. The pharmaceutical composition of wherein the antibiotic is neomycin.5. A pharmaceutical composition comprising:GLA; anda subtherapeutic dose of neomycin The disclosure generally relates to compositions comprising fatty acids including, for example, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and/or gamma-linolenic acid (GLA), alone or in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin or ocular infection.Scores of different bacterial species colonize the skin and other organs as normal flora. However, when the skin's normal continuity or other tissue microenvironment becomes disrupted, the resulting contusions, wounds, lesions, incisions, pockets, lacerations, and/or other disruptions can become infected by a wide variety of bacterial species, some of which have become or are rapidly becoming resistant to existing therapies. Accordingly, there exists a need for compositions that are more effective in the treatment of skin and oral infections.The present disclosure provides compositions comprising one or more long-chain polyunsaturated fatty acids agents (LC-PUFA) including, for example, DHA, EPA and/or GLA, used alone or in combination with antibiotic agents for the treatment of disease and/or disorders of the skin, eye or other organs.The present disclosure also provides methods ...

Подробнее
Номер записи: 94
05-06-2014 дата публикации

Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Номер: US20140155455A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharmaceuticals Ireland Ltd

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Подробнее
Номер записи: 95
05-06-2014 дата публикации

COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES IN A SUBJECT ON CONCOMITANT STATIN THERAPY

Номер: US20140155481A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. 1. A method of lowering triglycerides in a subject on stable statin therapy having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl comprising , administering to the subject on stable statin therapy from about 2 g to about 4 g per day of a pharmaceutical composition comprising at least 96% pure ethyl-EPA for a period effective to lower fasting triglycerides in the subject compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period.2. The method of wherein said period is about 1 to about 12 weeks.3. The method of wherein said period is about 1 to about 10 weeks.4. The method of wherein said period is about 1 to about 5 weeks.54. The method of any one of - wherein the subject has serum LDL-C levels of about 40 mg/dl to about 115 mg/dl at a baseline prior to administration of the composition.6. The method of wherein upon administering the composition to the subject daily for said period claim 5 , the subject exhibits a reduction in fasting VLDL-C compared to a fasting VLDL-C level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period.7. The method of claim 6 , wherein upon administering the composition to the subject daily for said period claim 6 , the subject exhibits at least a 20% reduction in fasting triglycerides compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period.8. The method of claim 7 , wherein upon administering the composition to the subject daily for said period claim 7 , the subject exhibits at least a 25% reduction in fasting triglycerides compared to a fasting triglyceride level in a subject maintained on stable statin therapy without concomitant ethyl-EPA for said period.9. ...

Подробнее
Номер записи: 96
14-03-2019 дата публикации

Methods of Reducing Apolipoprotein C-III

Номер: US20190076390A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre, Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing an APOC3 level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl , the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day ,wherein the subject is on a high statin efficacy regimen selected from the group consisting of about 20 to about 40 mg rosuvastatin, about 40 to about 80 mg atorvastatin, about 80 mg simvastatin, and about 40 to about 80 mg simvastatin plus about 5 to about 10 mg ezetimibe or the subject is on a medium statin efficacy regimen selected from the group consisting of about 5 to about 10 mg rosuvastatin, about 10 to about 20 mg atorvastatin, about 20 to about 40 mg simvastatin, and about 10 to about 20 mg simvastatin plus about 5 to about 10 mg ezetimibe.2. The method of claim 1 , wherein the APOC3 level is reduced by at least about 5%.3. The method of claim 1 , wherein the APOC3 level is reduced by at least about 15%.4. The method of claim 1 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.5. The method of claim 1 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.6. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.7. The method of claim 1 , wherein the reduction in APOC3 level is in comparison to control subjects having fasting triglycerides of about 200 mg/dl to about 499 mg/dl who have received the statin but not the pharmaceutical composition.8. The method of claim 1 , wherein the ...

Подробнее
Номер записи: 97
21-03-2019 дата публикации

METHODS OF REDUCING APOLIPOPROTEIN C-III

Номер: US20190083444A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre, Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing an APOC3 level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl , the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day.2. The method of claim 1 , wherein the APOC3 level is reduced by at least about 5%.3. The method of claim 1 , wherein the APOC3 level is reduced by at least about 15%.4. The method of claim 1 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.5. The method of claim 1 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.6. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.7. The method of claim 1 , wherein the reduction in APOC3 level is in comparison to control subjects having fasting triglycerides of about 200 mg/dl to about 499 mg/dl who have received the statin but not the pharmaceutical composition.8. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.9. The method of claim 1 , wherein the pharmaceutical composition comprises no more than about 10% claim 1 , by weight of all fatty acids present claim 1 , docosahexaenoic acid or a derivative thereof claim 1 , if any.10. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate and no more than about 2% claim ...

Подробнее
Номер записи: 98
02-04-2015 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND/OR 15-HETRE AND METHODS OF USE THEREOF

Номер: US20150093344A1
Автор: Climax John, Coughlan David, Manku Mehar
Принадлежит:

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema. 1. A composition for preventing or reducing the occurrence of erythema , the composition comprising a therapeutically effective amount of DGLA and/or 15-HETrE.2. The composition of claim 1 , wherein the composition comprises about 0.1 wt. % DGLA to about 20 wt. % DGLA.3. The composition of claim 2 , wherein the composition comprises about 10 wt. % DGLA claim 2 , about 1.0 wt. % DGLA claim 2 , or about 0.1 wt. % DGLA.4. The composition of claim 1 , wherein the composition comprises about 0.01 wt. % to about 50 wt. % 15-HETrE.5. The composition of claim 4 , wherein the composition comprises about 10 wt. % 15-HETrE claim 4 , about 1.0 wt. % 15-HETrE claim 4 , about 0.1 wt. % 15-HETrE claim 4 , or about 0.01 wt. % 15-HETrE.6. The composition of claim 5 , wherein the composition comprise about 0.1 wt. % DGLA to about 20 wt. % DGLA and about 0.01 wt. % to about 50 wt. % 15-HETrE.7. A photoprotective composition for preventing or reducing the occurrence of erythema claim 5 , the composition comprising i.) a therapeutically effective amount of DGLA and/or 15-HETrE; and ii.) a sunscreen active agent.8. The composition of claim 7 , wherein the composition comprises about 0.1 wt. % DGLA to about 20 wt. % DGLA.9. The composition of claim 8 , wherein the composition comprises about 10 wt. % DGLA claim 8 , about 1.0 wt. % DGLA claim 8 , or about 0.1 wt. % DGLA.10. The composition of claim 7 , wherein the composition comprises about 0.1 wt. % to about 50 wt. % 15-HETrE.11. The composition of claim 10 , wherein the composition comprises about 10 wt. % 15-HETrE claim 10 , about 1.0 wt. % 15-HETrE claim 10 , about 0.1 wt. % 15-HETrE claim 10 , or about 0.01 wt. % 15-HETrE.12. The composition of claim 7 , ...

Подробнее
Номер записи: 99
02-04-2015 дата публикации

Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same

Номер: US20150094370A1
Автор: Bill DOWNES, David Coughlan, John Climax, Mehar Manku
Принадлежит: DS Biopharma Ltd

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production.

Подробнее
Номер записи: 100